No retraction, correction or concern found when last checked on Oct 26, 2026.

Wnt Signaling in the Regulation of Immune Cell and Cancer Therapeutics

Muhammad Haseeb, Rameez Hassan Pirzada, Qurat Ul Ain and 1 more

Cells · 2019 · Review · CC BY

Abstract

Wnt signaling is one of the important pathways to play a major role in various biological processes, such as embryonic stem-cell development, tissue regeneration, cell differentiation, and immune cell regulation. Recent studies suggest that Wnt signaling performs an essential function in immune cell modulation and counteracts various disorders. Nonetheless, the emerging role and mechanism of action of this signaling cascade in immune cell regulation, as well as its involvement in various cancers, remain debatable. The Wnt signaling in immune cells is very diverse, e.g., the tolerogenic role of dendritic cells, the development of natural killer cells, thymopoiesis of T cells, B-cell-driven initiation of T-cells, and macrophage actions in tissue repair, regeneration, and fibrosis. The purpose of this review is to highlight the current therapeutic targets in (and the prospects of) Wnt signaling, as well as the potential suitability of available modulators for the development of cancer immunotherapies. Although there are several Wnt inhibitors relevant to cancer, it would be worthwhile to extend this approach to immune cells.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 26, 2026. Paragraph numbers are ours, so an answer can point at one.

1. Introduction

1Wnt signaling performs a wide variety of essential tasks in the human body by regulating cell differentiation, proliferation, embryonic growth, stem cell development, immune cell functions, and tissue repair and regeneration. Various communication mechanisms such as chemical signals exist between the Wnt protein and a receptor called Frizzled (FZD), to execute these tasks in a coordinated manner. In mammals, there are 19 distinct Wnt-type ligands (hereafter “Wnt ligands”), which bind to various receptors including 10 FZD proteins, and numerous co-receptors such as lipoprotein receptor–related proteins (LRP5 and LRP6). The Nusse laboratory at Stanford University has done tremendous work and gathered a large amount of information on Wnt signaling (see “The Wnt homepage” www.stanford.edu/group/nusselab/cgi-bin/wnt/). Wnt signaling is classified into canonical and noncanonical pathways: (1) the canonical one involves cadherin-associated protein β (β-catenin), T-cell factor (TCF), and lymphocyte enhancer-binding factor (LEF); and (2) the noncanonical pathway, includes the planar cell polarity (PCP) pathway and Wnt calcium pathway (Wnt–Ca2+). Dysregulation of the Wnt signaling cascade and aberrant expression of Wnt ligands causes several disorders such as autoimmune diseases, osteoarthritis, asthma, allergy, and cancer. Recently, immunologists reported in a number of studies that Wnt signaling and Wnt ligands play an essential and considerable role in the regulation of immune cells. Therefore, a detailed study is needed to understand the mechanisms of the Wnt signaling pathway and the impact of Wnt ligands on immune cell modulation and various diseases. Here, we review the mechanisms of Wnt signaling and the effects of Wnt ligands on immune cell modulation. First, we briefly explain the activation mechanisms of the canonical and noncanonical Wnt signaling pathways. Then, we discuss the involvement of Wnt signaling and recent findings of Wnt ligands and related proteins in the regulation of such immune cells as dendritic cells (DCs), natural killer (NK) cells, T cells, macrophages, and B cells. Next, we address the participation of Wnt signaling and the respective ligands in breast cancer, leukemia, gastrointestinal cancers (GCs), and brain cancers. Lastly, we highlight the current therapeutic targets in Wnt signaling and the possible suitability of the available modulators for the development of cancer immunotherapies.

2.1. Wnt–β-Catenin Signaling

2In Wnt–β-catenin signaling, activation of the cascade is triggered by the binding of a Wnt ligand (Wnt1, Wnt2, Wnt3, Wnt3a, Wnt7a, Wnt7b, Wnt8a, Wnt8b, Wnt10b, or Wnt16) to its respective FZD family receptor (ten such receptors in humans and mice) and low-density co-receptor LRP5 or LRP-6 (Figure 1). The activation of the Wnt receptor complex triggers downstream signaling, which causes the accumulation of β-catenin in the cytoplasm and its eventual translocation into the nucleus, where it can interact with transcription factors TCF and LEF and activate Wnt target genes cyclin D1 (CCND1), AXIN2, the Myc proto-oncogene, and dickkopf 1 (DKK1). When Wnt signaling is inactive, β-catenin levels are kept low by a destruction complex. This complex is composed of protein kinases, including casein kinase 1 (CK1), glycogen synthase kinase 3 β (GSK3β), adenomatous polyposis coli (APC), and axin. The activation of the Wnt–β-catenin signaling pathway is involved in many cellular functions: cell cycle regulation, cell proliferation, apoptosis, stem cell development, differentiation of progenitor cells, and immune cell regulation. Recently, it was reported that canonical Wnt–TCF signaling can regulate immune cell–mediated responses of T cells and DCs and stabilizes immunity. Consequently, the aberrant activation of this cascade causes various immune disorders and cancers.

2.2. Noncanonical Wnt Signaling

3In the noncanonical Wnt pathway, signaling is activated upon binding of a Wnt5a class ligand (Wnt4, Wnt5a, Wnt5b, Wnt6, or Wnt11). The noncanonical Wnt signaling pathway is classified into 2 pathways: the PCP pathway and Wnt–Ca2+ pathway (Figure 1). The PCP pathway takes part in the regulation of cellular polarization, adhesion, stem cell maintenance, embryonic development, and cell invasion and migration. Molecular factors of the Wnt signaling pathway, typically Wnt4, Wnt5a, Wnt5b, and Wnt11, bind to receptors of the FZD family, receptor-like tyrosine kinase (RYK), receptor tyrosine kinase–like orphan receptor 1 or 2 (ROR1 or ROR2), and protein tyrosine kinase 7 (PTK7), which trigger the noncanonical PCP pathway. There are several other important components of the Wnt–PCP pathway including Dvl1-3, prickle-like proteins 1–4 (PRICKLE1–4), Vang-like proteins 1 and 2 (VANGL1/2), cadherin EGF LAG seven-pass G-type receptors 1–3 (CELSR1–3), and small G proteins Rho and Ras-related C3 botulinum toxin substrate 1 (Rac1). In the PCP pathway, signals are transformed to actin cytoskeletal movements through Rho and Rac, and then, Rho-associated kinase activates Jun N-terminal kinase (JNK)-dependent transcription. Recently, it was reported that receptor RYK might regulate the development of NK cells, and the role of RYK in hematopoiesis was proposed. Moreover, noncanonical Wnt signaling via receptor tyrosine kinases (RTKs), such as ROR1, ROR2, and RYK, activates phosphatidylinositol-3 kinase–AKT (PI3K–AKT) signaling and is involved in numerous cancers including breast cancer, GCs, leukemia, and brain cancer.

4In the noncanonical Wnt–Ca2+ pathway, ligand Wnt5a interacts with receptor FZD along with co-receptor ROR1 or ROR2, causing a release of Ca2+ from the endoplasmic reticulum and activating phospholipase C (PLC) through G protein and SEC14-like protein 2 (SEC14L2), resulting in the formation of 1,2-diacylglycerol (DAG) and inositol 1,4,5-triphosphate (IP3). Previously, it has been revealed that Wnt ligands activate several downstream Ca2+-dependent enzymes such as calcineurin, protein kinase C (PKC), and calmodulin-dependent kinase II (CaMKII). Moreover, calcineurin, PKC, and CaMKII participate in various cellular phenomena including cell differentiation, migration, and adhesion through the regulation of transcription factors myocyte enhancer factor 2 (MEF2) and nuclear factor of activated T cells (NFAT).

5Noncanonical Wnt ligands substantially participate in the inhibition of canonical signaling; calcineurin and CaMKII stimulation triggers Nemo-like kinase (NLK) and inhibits Wnt–β-catenin signaling. It has been stated that the Wnt–Ca2+ signaling pathway is strongly associated with tumorigenesis and cancer progression. Several studies show that ligand Wnt5a often activates the Wnt–Ca2+ pathway in cancer cells and higher expression of Wnt5a suppresses breast and colorectal cancer (CRC). Collectively, the detailed mechanisms of action of canonical and noncanonical Wnt ligands, and their signaling cascades in immune cells with respect to diseases and treatments, are still debated and require research for the subsequent development of therapeutics.

3. Wnt Signaling in Immune Cell Regulation

6The development and regulation of immune cells originate from hematopoietic stem cells (HSCs). The latter can retain self-renewal enabling differentiation and regeneration to produce mature blood cells is critical to survival. During development, murine embryonic hematopoiesis takes place at different anatomical sites (extraembryonic yolk sac, placenta, and aorta-gonad-mesonephros (AGS)). These HSCs then move into and seed different organs; normal adult hematopoiesis occurs in bone marrow and follows a series of developmental steps (Figure 2a). Furthermore, the response of HSCs can be divided into two phases: (a) Long-term HSCs (LT-HSCs) possess the capacity for both differentiation and self-renewal for a long time, (b) and short-term HSCs (ST-HSCs) can perform restoration for a limited time. These ST-HSCs give rise to multipotent progenitor cells, myeloid lineage cells (macrophages and granulocytes), and lymphoid progenitor cells (NK cells, dendritic cells, B cells, and T cells), while DCs have partial lineage connections. In this review, we mainly focus on the role of Wnt signaling in lymphoid and myeloid progenitor cells.

7In this context, Wnt signaling is a key player and a vital part of immune cell modulation, development, activation, regeneration, and downregulation (Figure 2b). The involvement of Wnt signaling in the immune system was initially reported in relation to T-cell development in the thymus. The Wnt–β-catenin signaling pathway is widely studied because it helps to direct immune cell infiltration and is looming large as a new putative target for molecular therapeutics of cancer.

3.1.1. Wnt Signaling in DCs

8DCs are antigen-presenting cells of the mammalian immune system that regulate an adaptive immune response. DCs are essential for the maintenance of the balance between tolerance and immunity, and the outcome of an immune response is determined by the type of released cytokines. The ability of DCs to induce both pro- and anti-inflammatory responses is due to the existence of various recently discovered regulatory mechanisms, including the cross-talk between Wnt–β-catenin and Toll-like receptor (TLR) cascades. A study indicates that both Wnt signaling and Notch signaling promotes differentiation into DCs in humans and mice, both in vivo and in vitro. Notch signaling is an upstream regulator of the Wnt pathway in HSCs via the upregulation of the FZD family of Wnt receptors, which is regulated by the CSL (RBP-Jκ) transcription factor. Co-receptors LRP5 and LRP6 are critical mediators of the canonical Wnt signaling pathway. On the other hand, specific ablation of LRP5 and LRP6 in DCs is associated with delayed tumor progression and enhanced host anti-tumor immunity. The Wnt pathway conditions DCs into a regulatory state when they surround a tumor microenvironment (TME) and suppress host immune activity against the tumor. Some members of the Wnt signaling family Wnt3a, Wnt5b, and Wnt16 activate the β-catenin–TCF pathway in DCs. The activation of Wnt3a or deletion of GSK-3β also stimulates the Wnt–β-catenin pathway and the specific inhibitor SB216763 suppresses GSK-3β activity.

9A study has been conducted to further discern the effect of the Wnt–β-catenin signaling pathway on regulatory versus inflammatory responses, where specific ablation of β-catenin in DCs increased inflammatory responses. Consequently, β-catenin is associated with a tolerogenic state and helps to control colitis in a murine model. Accordingly, the mechanism behind immunological tolerance driven by DCs attributed to β-catenin has been elucidated by expression of vitamin A–metabolizing enzymes and interleukin 10 (IL-10) in combination with such signaling molecules as Fas, phosphoinositide-specific phospholipase C (PLCγ2), mitogen-activated protein kinases (MAPKs), TLRs, and PI3K with AKT. An alternate method of β-catenin–controlled immunological tolerance mediated by DCs is the induction of a specific disruption in the interactions involving homophilic E-cadherin. Although the ablation of homophilic E-cadherin induces maturation of DCs, it inhibits the production of proinflammatory cytokines, thus resulting in the differentiation of progenitors into IL-10–producing cluster of differentiation 4–positive (CD4+) T cells. In a murine model, Wnt3a and Wnt5a induce activation of a tolerogenic response among DCs by altering their responses to lipopolysaccharide; on the contrary, they do not cause any changes in DC maturation. Moreover, a melanoma-derived Wnt ligand (Wnt5a) facilitates the activation of β-catenin signaling, which causes an increment in the production of indoleamine 2,3-dioxygenase (IDO) in DCs, leading to the increased production of regulatory T cells.

10In cancer, immunosuppression is promoted by dysfunctional DCs in the TME. Increased levels of Wnts in the TME can trigger paracrine signaling and regulate host antitumor immunity. In a TME, DCs metabolize vitamin A to retinoic acid. In addition, high levels of IL-10 and TGFβ expressed by DCs induce immune tolerance through CD4+ and CD8+ T cells. Of note, IL-10 production is dependent on β-catenin/TCF4 and mTOR pathways. Furthermore, a recent study suggests that Wnt1 induces a tolerogenic response in lung adenocarcinoma. Wnt1 inhibits CC and CXC motif chemokine transcription in DCs via the downregulation of transcription factor Cebpb, which is inversely related to T-cell abundance and thereby induces a tolerogenic response in lung cancer. As discussed above, enhanced Wnt signaling promotes tumor progression and may contribute to immune evasion. Thus, further studies are needed to investigate distinct ways to alter Wnt signaling in tumor cells; this approach may cause beneficial changes in the TME and improve cancer treatment.

3.1.2. Wnt Signaling in NK cells

11The Wnt–β-catenin signaling pathway has been implicated in the development of NK cells and activates natural killer T (NKT) cell development and function. Wnt3a primarily signals via the β-catenin dependent pathway, and a study indicates that exposure to Wnt3a or lithium chloride enhances NK-cell production and changes the differentiation potential of human thymic progenitors. In contrast, the coculturing of human CD34+ CD38−/low HSCs with OP9 stromal cells expressing Wnt3a induces a reduction in the number of NK cells isolated from these HSCs. Nonetheless, active Wnt3a signaling in OP9 stromal cells causes an alteration in the transcriptional profile of these stromal cells, suggesting that the variation in the stromal-cell phenotype could contribute to the reduction in the differentiation into NK cells. The altered outcomes of NK-cell differentiation because of Wnt3a expression highlight the role of other (unidentified) ligands and pathways that are yet to be explored. Human CD34+ HSCs when cultured under the conditions favorable for differentiation into NK cells with hydrocortisone, stromal cells, and cytokines (IL-3, IL-7, IL-15, Fms-related tyrosine kinase 3 ligand [FLT3L], and stem cell factors) show increased mRNA expression of LEF1 and TCF1 in contrast to suboptimal differentiation conditions with cytokines only. Nonetheless, any blockage of the Wnt signaling pathway negatively influences their differentiation into NK cells. For example, the introduction of DKK1, which is a natural inhibitor of β-catenin dependent Wnt signaling, leads to a reduction in the number of NK cells, which normally develop under these conditions. Another factor, such as DKK1, DKK2, or DKK4, inhibits the Wnt signaling pathway, where DKK3 does not show any affinity for LRP6, and for this reason, its function in Wnt signaling remains elusive. Furthermore, a mouse study has revealed that both TCF1 and LEF1 contribute significantly to NK-cell development, and TCF1 plays a more prominent part in NK-cell development. β-Catenin–deficient mice have a decreased number of NK cells in vivo as compared to the control—these data are suggestive of an important function of β-catenin, LEF1, and TCF1 in HSCs.

12Moreover, CD1D-restricted NKT cells have a crucial role in tumor rejection and immune regulation and are dependent on the regulatory relation between LEF1 and the CD1D gene. A study on two leukemia cell lines-Jurkat cells (T lymphocytes) and K562 (myelogenous leukemia cell line) has unveiled the underlying mechanism of interaction in which LEF1 specifically binds to the CD1D promoter and regulates CD1D expression. Nevertheless, an activated NKT cell produces cytokines that can regulate other immune cells (DCs, NK cells, and T cells) surrounding the TME by secreting IL-4 and IFNγ thereby implementing anti-tumor responses.

3.1.3. Wnt Signaling in T cells

13T cells are a type of lymphocyte that, according to recent findings, have a significant function in CD4+ and CD8+ T-cell–mediated adaptive immune responses. In the case of viral infection, naïve T cells trigger the formation of T effector cells that are detrimental to pathogens via cytotoxicity and also form memory T cells, which respond more efficiently to any future infection. Memory T cells downregulate the activity of T effector cells in an antigen-independent manner by utilizing IL-7 and IL-15. On the contrary, in cancer, T cells become dysfunctional due to consistent exposure to an antigen in the TME and start to express inhibitory receptors, including LAG-3, Tim-3, CTLA-4, and PD-1.

14In T cell development and regulation, the contributing pathways include Wnt/β-catenin, SMAD, signal transducer and activator of transcription 3 (STAT3), and Notch signaling pathways. Nevertheless, the first evidence of the participation of Wnt signaling in the immune system originates from the studies on T-cell development in the thymus. Wnt signaling has been reported to perform a significant function in thymopoiesis. During the initial phases of thymocyte development in mice, high-mobility group (HMG) transcription factors of the Wnt pathway (TCF1 and LEF1) are known to be essential for the regulation of thymocyte development and maturation. Precursor T cells mature in the thymus, owing to the presence of Delta-like ligands for Notch, which is essential for T-cell development in humans and mice. One of the downstream target genes of Notch signaling is TCF1, which subsequently restrains LEF1 to stop the transformation of thymocytes; in TCF1-deficient mice though, it stimulates T-lineage maturation. By direct ablation of double-positive (DP) thymocytes, researchers have found that TCF1 and LEF1 deficiency diminishes the maturation of CD4+ T cells into the CD8+ cell lineage. Both TCF1 and LEF1 interact with β-catenin to regulate the DP (CD4+CD8+) cell differentiation into CD4+ T cells, and in this process, Th-POK is an upstream regulator. In contrast, CD8+ T-cell maturation and development are regulated by the crosstalk between TCF1 and RUNX3 serving to silence CD4 gene expression. Histone deacetylases HDAC1 and HDAC2 and transcription factor Th-POK are reported to maintain the integrity of CD4+ T cells by repressing the genes associated with the CD8+ lineage. Similarly, a study has revealed that Wnt transcription factor LEF1 and TCF1 are important for establishing CD8+ T-cell identity due to HDAC activity, by downregulating RAR-related orphan receptor C (RORC), forkhead box P3 (FOXP3), and CD4 in a mouse model. Moreover, TCF1 has multiple isoforms in which it possesses a long chain of the β-catenin N-terminal domain. The crosstalk between β-catenin and the long N-terminal domain maintains thymocyte survival instead of thymic maturation as identified in TCF1 isoform–deficient (p45−/−) mice. During thymopoiesis, the importance of β-catenin has been confirmed because it upregulates interleukin 7 receptor subunit α (IL7R-α) in thymocytes through positive selection. A study has shown that by means of soluble FZD-type receptors as a decoy, thymocyte development can be stopped in murine thymic organ culture possibly owing to the disruption of Wnt signaling. Both TCF1 and LEF1 are necessary because targeted gene disruption completely blocks thymocyte differentiation. Similarly, in another study, double mutation LEF1-/-TCF1-/- in mice induced T-cell differentiation arrest at an immature CD8+ single-positive stage, in cells expressing T-cell receptor beta (TCRβ) but with reduced TCRα gene transcription. The transition of thymocytes from double-negative (DN) to DP is regulated by Wnt signaling. The expression of naturally occurring inhibitor of β-catenin and TCF (ICAT) blocks the thymocyte transition from the DN to DP stage, but does not have any effect on later developmental stages. On the contrary, DKK1 inhibits the binding of Wnt to co-receptors LRPs and stops the thymocyte differentiation in a dose-dependent manner at the DN stage. As for β-catenin, its function in CD8+ T cells is to induce stem cell–like properties (self-renewal and differentiation into effector cells); similarly, TCF1 induces the same functionality in these cells, and silencing of its expression eliminates the stem cell–like properties from CD8+ T cells. Accordingly, the Wntβ-catenin pathway positively correlates with the progression of a tumor and metastasis. It is a significant oncogenic pathway that induces immune evasion and is thereby negatively associated with the effector CD8+ T cell infiltration at the tumor site.

15In a mouse model of lymphocytic choriomeningitis mammarenavirus chronic infection, among CD4+ T cells, memory cell (Th1, Tfh) production is regulated due to the presence of TCF1 long isoforms. Moreover, the induction of the GATA-3-1b isoform by TCF1 affects the differentiation of Th2 cells, and its absence can protect mice from ovalbumin-induced asthma. Wnt3a has been found to activate Th2-cell differentiation via β-catenin and special AT-rich sequence binding protein 1 (SATB1). In contrast, Th17 cells have been demonstrated to eliminate tumors and to express large amounts of TCF7 and β-catenin while manifesting the characteristics similar to those of early memory CD8+ T cells. Microarray analysis of chemokine ligand CXCL has confirmed that the expression of Wnt5a in human CD4+ T cells is necessary for T-cell migration.

3.1.4. Wnt Signaling in B cells

16The Wnt pathway is associated with the regulation of various essential cellular processes including lymphopoiesis, although its role in B cells is perhaps less understood, especially the role in B-cell progenitors in bone marrow as compared to Tcells in the thymus. The early stage of B-cell growth is regulated by canonical and non-canonical Wnt pathways; however, its aberrant activation has oncogenic complications. B-cell proliferation is regulated by Wnt signals through LEF1, and a study revealed that mice deficient in LEF1 have defects in pro-B-cell proliferation and survival both in vivo and in vitro. Due to increased c-Myc and Fas transcription, the sensitivity to apoptosis is higher. FZD9−/− mice have a defect in B-cell lymphopoiesis; this defect negatively affects B-cell development in bone marrow, especially in cycling pre-B cells. Nonetheless, in the case of human B-cell progenitors, Wnt3a stimulation negatively affects the proliferation potential of B cells despite increased β-catenin levels. Similarly, there is antagonism between canonical Wnt signaling and Wnt5a signals in the thymus because Wnt5a signals via noncanonical pathways, thereby inhibiting the proliferation of B cells in a cell-autonomous manner. On the other hand, the absence of the wild-type Wnt5a allele induces B-cell lymphomas and clonal myeloid leukemia in hemizygous mice. Wnt5a gene deletion or loss of its expression has been observed during the analysis of human primary leukemia. Similarly, Hodgkin lymphoma (HL) originates from transformed Reed–Sternberg (RS) cells, which usually lack B-cell receptor expression. Additionally, HL cell lines express other components of the Wnt pathway and increased levels of cytoplasmic and nuclear β-catenin. Nevertheless, the activation of GSK-3β in classical HL (cHL) consequently inhibits Wnt-β-catenin signaling.

17In a TME, aside from the production of cytokines and antibodies, B cells play a versatile role in the modulation of innate immune and T-cell responses. By contrast, tumor-infiltrating B lymphocytes have been identified in solid tumors and play a significant role in cancer suppression by releasing immunoglobulins and activating T cells to directly kill cancer cells. The expression of specific markers on different B-cell subtypes has contradictory effects on pro- or antitumorigenic processes. A recent study revealed that during an early phase of tumor progression, B cells produce antibodies that cause DCs and cytotoxic T cells to control tumor growth. On the contrary, regulatory B cells promote a pro-tumorigenic response to facilitate tumor progression. Notably, a study has been performed on acute myeloid leukemia (AML) where B cells include a higher proportion of regulatory B cells and display surface markers CD19, CD24, and CD38. Nonetheless, less attention is given to the investigation of the role of Wnt signaling in B-cell development and regulation along with its participation in carcinogenesis. Therefore, further research is needed in the context of B cells to develop new treatment modalities for cancer.

3.2.1. Wnt Signaling in Macrophages

18Macrophages are essential for homeostasis in most of organ systems for tissue repair and development; additionally, these cells provide defense against pathogens, cancer, and chronic inflammation. The involvement of macrophages in a diverse array of cellular functions gives these cells plasticity to adapt well to their microenvironment. In many organs after tissue injury, macrophages establish a tissue repair program, and the associated Wnt ligands are essential players in tissue regeneration and fibrosis. Wnt-specific ligands also play a regulatory part during infection or inflammation. It is speculated that in response to isolated TLR ligands, NF-κB activation, or Mycobacterium tuberculosis, macrophages express Wnt5a and its receptor FZD5. Similarly, the expression of Wnt5a and FZD5 has been observed in biopsy samples from patients with sepsis. Another study revealed bacterial infection (with Francisella tularensis) in murine peritoneal macrophages that were caused by the activation of GSK3β both in vivo and in vitro. Inhibition of GSK3β leads to a noticeable reduction in the production of anti-inflammatory cytokines such as tumor necrosis factor α (TNFα), IL-12p40, and IL-6. According to these results, GSK3β acts as a regulator that modulates the inflammatory responses and could be harmful to the host during infection by F. tularensis, thereby pointing to novel therapeutic targets in tularemia. Macrophages and Wnt proteins are involved in cardiac repair as observed in mice after myocardial infarction. A study on mice has revealed that the specific ablation of the Wntless (WLS) protein, which is essential for the secretion of Wnt ligands, improves heart function and cardiac repair after an ischemic injury caused by myocardial infarction. These findings point to a potential therapeutic target for the improvement of cardiac repair via targeting of natural Wnt inhibitors. The intestinal stroma is mainly composed of macrophages, which have been found to perform a pivotal function in the coordination of intestinal repair because of the presence of macrophage-derived Wnt signaling. To further unravel the macrophage-derived Wnt signaling, porcupine O-acyltransferase (PORCN) depleted mice have been studied and show normal intestinal morphology but are hypersensitive to radiation injury as compared with wild-type littermates. In acute murine colitis treated with 2,4,6-trinitrobenzene sulfonic acid, the STAT6-dependent macrophage phenotype mediates mucosal repair via activation of the Wnt signaling pathway. In a STAT6−/− murine model treated with 2,4,6-trinitrobenzene sulfonic acid, impaired wound healing was observed and yielded a reduction in mRNA expression of Wnt ligands (Wnt2b, Wnt7b, and Wnt10a) in cells of the lamina propria and mucosa. Furthermore, Wnt7b has a repair function because its somatic deletion in macrophages negatively influences tissue repair and kidney regeneration after ischemic injury in a mouse model. The expression of the Wnt7b protein in myeloid cells induces tumor progression, metastasis, angiogenesis, and enhances the functionality of tumor-associated macrophages (TAMs) in humans and mice. In myeloid cells in an MMTV-PyMT mouse model, Wnt7b gene deletion induces a dramatic reduction in mammary gland tumor volume and mass as compared to wild-type mice. On the other hand, it has been reported that the induced expression of Wnt3a causes macrophages to engulf hepatocyte debris during liver regeneration. This process activates the commitment of murine hyperspiny purkinje cells to the hepatocytes through the β-catenin–dependent pathway in a mouse model. Wnt5a is important for macrophage-induced invasiveness because of its proteolytic activity, along with its ability to regulate tumor cell migration, insulin resistance, atherosclerosis, and obesity.

19A proinflammatory activity of Wnt5a in macrophages has been demonstrated too, after the identification and internalization of Chandipura virus or Escherichia coli by receptor CD14. The Wnt5a–FZD5–Rac1–p65 signaling cascade consequently activates TLR signaling in bone marrow-derived macrophages and in a murine macrophage (RAW 264.7) cell line. Wnt5a induces a proinflammatory response not only during infection and organ repair or injury; for example, a study suggests that Wnt5a may activate an immunosuppressive response in macrophages in both humans and mice. In humans, the differentiation into M1-type macrophages is inhibited via Wnt5a-induced suppression of the NF-κB pathway. Therefore, this triggers the production of immunosuppressive cytokines (e.g., TGF-β and IL-10) and induces an M2 macrophage like phenotype. The M2-like phenotype acquired by TAMs conducive to the production of inflammatory cytokines IL-23 and IL-17, which have been reported to positively promote tumor growth and progression. Tumor cells have been demonstrated to reprogram macrophages into a distinct TAM population via the exosomal pathway. This pathway plays an important role in the transport of miR-1246 from P53-mutant colon cancer cells to peripheral macrophages—this process induces M0 and M2 macrophages to produce TGF-β, IL-10, VEGF, and CCL2.

20In brief, the actions of Wnt ligands in macrophages can significantly participate in the repair of tissue injury, although the reparative function is not universal. This is because not all Wnt ligands have the same biological activities and functions. Therefore, to obtain full mechanistic insight into each Wnt ligand’s activity and its signaling components, additional studies are necessary, which will further clarify the participation of Wnt in various biological functions.

3.2.2. Wnt Signaling in Granulocytes

21Granulocytes (mast cells, neutrophils, eosinophils, and basophils) contribute significantly to inflammation both in immune regulation and pathogen removal; they differentiate and mature in bone marrow before entering the blood circulation where they remain in the G0 phase in the absence of extracellular stimuli and undergo apoptosis. As for Wnt signaling, it has been identified as a key process in the function of granulocytes. However, the mechanism is less studied. Moreover, neutrophils are among the first lines of defense because they are recruited to an area of infection or injury, and Wnt5a mediates this process. By contrast, in eosinophils, Wnt5a in combination with other factors promotes cell proliferation, as observed in airway smooth muscle cells isolated from asthma patients. Here, we briefly focus on mast cells.

22Mast cells are the type of immune cells that reside in connective tissue throughout the body and significantly partake in the regulation of adaptive and innate immunity. These cells originate from HSCs and differentiate within the tissue environment upon migration to peripheral tissues. Nevertheless, an interesting similarity between mast cells and HSCs has been uncovered, including c-Kit expression and self-renewal. Wnt5a has been identified as a significant factor in this context because Wnt5a promotes the maturation of mast cells through the Wnt-β-catenin pathway. Furthermore, mast cells contribute as a promoter and inhibitor of tumor growth, but the exact mechanism is not well understood. The production of proangiogenic factors such as IL-8, TNF-α, vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), and transforming growth factor β (TGF-β) promotes angiogenesis, whereas anticancer mediators include IL-1, IL-6, chymase, TNF-α, and tryptase. Further studies are needed to explore the activities of Wnt in granulocytes for the development of therapeutics.

4. Wnt Signaling in Cancer

23Wnt signaling has been identified as a key player that governs several developmental and cellular processes such as cell proliferation, migration, and fate determination. Nonetheless, slight variation in this pathway could be detrimental by inducing cancer and therefore has been recognized as a key mechanism in cancer biology. There are several aberrant regulatory processes affecting Wnt signaling components, e.g., mutations, overexpression, and downregulation (Figure 3). There are numerous studies on the role of Wnt in cancer, however in this review we mainly focus on leukemia and breast, brain, and GCs.

4.1. Breast Cancer

24Wnt signaling is activated in approximately 50% of breast tumors and is associated with reduced overall survival of the patients. Wnt–β-catenin signaling is deeply involved in the initiation and progression of triple-negative breast cancer (TNBC). However, other breast cancer subtypes overexpress nuclear β-catenin. Wnt signaling not only induces breast development during pregnancy, but also plays a crucial part in the oncogenic transformation of mammary tissue. The overexpression of FZD7 and Wnt7a is triggered by ∆Np63, which then activates stem cells that promote basal-like breast cancer. The overexpression of R-spondin 2 initiates mammary tumors in mouse models. Furthermore, ROR1 is not present in normal mammary tissue, but is overexpressed in breast cancer cells. Thus, it leads to rapid epithelial–mesenchymal transition and is linked to a low survival rate. The up-regulation of PD-L1 in TNBC cancer stem cells is therefore associated with Wnt gene activation. Furthermore, clinical dataset analysis has revealed PD-L1 overexpression in TNBC tumors: a tradeoff between more enriched stem cells and enhanced Wnt activity.

25Besides, further updates have uncovered a relationship between resistance to a PI3K inhibitor and the upregulation of the canonical Wnt pathway—these phenomena are associated with poor prognosis among breast cancer patients. Additionally, Wnt1-inducible signaling pathway protein 1 (WISP1) can transcriptionally block N-Myc downstream-regulated gene 1 (NDRG1) resulting in breast cancer metastasis. Wnt pathway-driven processes can cause population heterogeneity of mammary breast cancer cells, among which the luminal subtype secretes Wnt1, which is essential for the propagation of a tumor and for cancer recurrence. Nevertheless, deficiency of LRP5 results in a delay in Wnt1-triggered tumorigenesis followed by a reduction in progenitor cell accumulation. On the other hand, DKK1 or DKK3 deficiency induces the self-renewal of progenitor cells by initiating the β-catenin pathway. In human breast cancer, the CD44(+) CD24(−/low) lineage shows high tumorigenicity, and both canonical and noncanonical Wnt signaling plays a crucial role in the implementation of epithelial–mesenchymal transition (EMT) and in the stem cell phenotype.

26A Wnt pathway crosstalk is substantial in breast cancer; for example, in the Hippo pathway, a transcriptional coactivator called WW domain binding protein 2 (WBP2) forms a network with YAP, TAZ, and β-catenin, which then promotes TCF-induced malignancy. These findings suggest that the presence of a polyclonal cell population in mammary tumors is due to Wnt activity in a specific subpopulation.

4.2. Leukemia

27In recent years, it has become clear from various findings that the disruption of the Wnt pathway is important for the progression of hematological cancers. Normal HSCs rely on the controlled regulation of Wnt signaling because it is a critical regulator of differentiation and self-renewal, whereas increased Wnt pathway activity is found in major leukemia. AML is one of the most common leukemia with balanced translocations t(8;21). In AML, galectin-9-induced autocrine T-cell immunoglobulin mucin-3 (TIM-3) signaling stimulates LRP6 signalosome formation and the accumulation of β-catenin in the nucleus. Accordingly, exosomes extracted from the plasma of AML patients show high levels of TGF-β1 and suppress NK-associated cytotoxicity. Notably, tumor-derived exosomes are critically involved in the suppression of immune cells by utilizing CD8+ anti-tumor effector cells. An exosomal profile can be used for disease prognosis and facilitates the characterization of a therapeutic outcome.

28In mixed-lineage leukemia fusion positive mouse model, HSCs give rise to myeloid progenitor cells and leukemia-initiating cells (LICs) after progression via pre-LIC state. β-Catenin is crucial for the progression from a pre-LIC to the LIC state and for the self-renewal of LICs. Chromosomal aberrations affect canonical Wnt signaling because of frequent AML translocations (PML-RARα, AML1-ETO, and mixed-lineage leukemia [MLL]-AF9), which have been identified in derived cell lines and clinical samples. The crosstalk of Wnt and NOTCH also promotes leukemic transformation of HSCs because of an interaction of β-catenin with forkhead box protein O1 (FoxO1) in osteoblasts which upregulates jagged1.

29The most common type of childhood leukemia is acute lymphoblastic leukemia (ALL), where bone marrow is infiltrated by immature lymphoblasts expressing T-cell immunophenotypic surface markers. As for T cells, in ALL, most LICs harbor mutations that activate the Notch signaling pathway. Furthermore, the presence of canonical Wnt signaling in thymocytes and HSCs along with c-Myc amplification induces β-catenin-dependent and Notch-independent activation of T-cell acute lymphoblastic leukemia (T-ALL). In Notch1-induced T-cell leukemia, the presence of high proportions of leukemic stem cells correlates with activated Wnt signaling. Canonical Wnt signaling not only specifically induces tumorigenesis in T-ALL subsets but also takes part in LIC self-renewal. A study on a mouse model of Notch1-mediated T-ALL confirms that LICs feature increased Wnt activity and genetic inactivation of β-catenin causes a reduction in the number of LICs in these tumors.

30Chronic lymphocytic leukemia (CLL) is the most common hematological cancer and is characterized by the accumulation of dysfunctional but morphologically mature CD5+ cells. In CLL cells, canonical Wnt signaling is active, whereas its inhibition induces apoptosis in vitro. Apart from the silencing by a Wnt-inhibiting factor, such as DKK1 or DKK2, the mutation in a Wnt pathway-associated gene (for example BCL9 or FZD5) accounts for 14% of studied cases. The overexpression of Wnt3, Wnt5b, Wnt6, Wnt10a, Wnt14, Wnt16, LRP5 and LRP6, LEF1, ROR1, or receptor FZD3 in CLL has been reported, contrary to normal B cells. These findings validate our notion that the survival of CLL cells relies on active Wnt signaling. Moreover, the exosomes surrounding a CLL cell microenvironment contain noncoding Y RNA hY4 in abundance. These exosomes can be utilized by monocytes to activate the TLR cascade and secrete large amounts of CCL2, CCL4, IL-6, and PD-L1 to promote CLL progression.

31Multiple myeloma has been characterized as the second most common hematological cancer associated with the aberrant Wnt signaling. Nonetheless, no oncogenic Wnt pathway mutation has been identified, indicating Wnt signaling stimulation in an autocrine or paracrine manner in a bone marrow microenvironment. In hematological cancers, the cross-talk between innate and adaptive immunity is critical, and a deep understanding of this relation will facilitate the development of new therapeutics. In major leukemia, the presence of active canonical Wnt signaling is important for tumor initiation, progression, maintenance, and for the survival of LICs.

4.3. Gastrointestinal Cancers (GCs)

32These cancers are among the most prevalent malignant tumors worldwide and are a prominent cause of cancer-related deaths. The causative mutations found in the majority of colorectal tumors are associated with the following pathways: Wnt, TP53, PI3K, MAPK, and TGF-β. Accordingly, other mutations in the Wnt pathway are also associated with CRC, including transcription factor 7–like 2 (TCF7L2), Wilms tumor gene (FAM123B), and CTNNB1. The mutation driving Wnt signaling in CRC is the loss of the APC gene. The oncogenesis of CRC can be modeled ex vivo in human-engineered intestinal organoids by means of the genome-editing CRISPR/Cas9 technology. Moreover, studies on CRC tumors have uncovered different APC mutations at specific levels of the canonical Wnt pathway, and these mutations are associated with particular tumor locations within the proximity of the large intestine. CRC cells can regain their normal function upon a reversible knockdown of APC with short hairpin RNA. In contrast, exosome-mediated communication in the TME also promotes tumor progression. Patients with colon cancer show a higher concentration of miR-203 in plasma exosomes, which triggers the differentiation of monocytes into M2-TAMs, consequently providing a favorable environment for tumor progression. Accordingly, TAMs are regulated by tumor-derived exosomes, which influence host immune function and promote tumor spread to distant organs.

33Hepatocellular carcinomas primarily harbor a missense mutation or insertions/deletions within CTNNB1 exon 3, thereby inducing defects in the production of β-catenin, which remains hypophosphorylated at Thr41, Thr45, Ser33, and Ser37 and hence is undegradable. Helicobacter pylori infection is another major causative factor of GCs because it promotes Wnt–β-catenin signaling by activating cytotoxin-associated gene A (CagA), which induces cancer stem cell–like characteristics in GCs as β-catenin specifically binds to the promoter regions of OCT4 and NANOG. Additionally, H. pylori–induced human GC is also associated with SOX9 expression, which eventually makes cancer cells responsive to β-catenin–dependent signaling. Erythropoietin-producing hepatoma receptor A2 (EphA2) has been reported to enhance β-catenin nuclear localization and induces c-Myc transcription, whereas Dvl2 mediates EphA2–axin1 signaling by interacting with the tyrosine domain of EphA2 in GC cells. Noncanonical signaling through Wnt5a also substantially partakes in GC progression: leucine-rich DVL associated protein mediates Wnt5a-triggered laminin γ2 expression via JNK and Rac1 stimulation.

34The activation of Wnt signaling has been detected in cholangiocarcinoma, and the validated mutations identified so far are an inhibitory ring finger protein 43 (RNF43) mutation, overexpression of Wntless, and hypermethylation of secreted frizzled-related protein 2 (SFRP2). Furthermore, osteopontin, a chemokine-like glycoprotein, has been found to enhance Wnt signaling in cholangiocarcinoma upon activation of the MEK–MAPK1 pathway via Ser675 phosphorylation and nuclear localization of β-catenin. Wnt-secreting macrophages are present around the TME to maintain strong Wnt signaling. The activity of SFRP2, a Wnt signaling inhibitor, is silenced in cholangiocarcinoma because of the hypermethylation of its gene. Recently, immunohistochemical analysis was performed to evaluate the expression of FZD5, CK1, Wnt5a, axin, GSK3β, ubiquitin, c-Myc, and cyclin D1—the results obtained are still unclear. Nonetheless, higher expression of components of the canonical Wnt pathway has been identified in samples of human gastric carcinomas.

4.4. Brain Cancer

35The Wnt–β-catenin signaling pathway contributes significantly to various stages of brain development and remains crucial in the adult brain. In neuro-oncology research, the mechanism of the Wnt pathway at a molecular level has piqued much interest among investigators. Wnt signaling controls and regulates anterior–posterior axis formation and neural differentiation during early vertebrate development. By contrast, abnormal Wnt signaling in neural stem cells (NSCs) stimulates malignant transformation and initiates the formation of brain tumors. For example, the prolonged activation of β-catenin augments neural progenitor cell proliferation in vivo, whereas its deletion reduces their proliferative capacity. Additionally, Wnt3a upregulates Wnt signaling, and thus the clonogenic potential of NSCs increases. Glioblastoma multiforme (GBM) is among the most lethal and common central-nervous-system tumors. GBM is resistant to treatment because it is distinguished by enhanced cell proliferation and extensive angiogenesis. The prevalent mutation characterized in GBM is homozygous deletion of FAT atypical cadherin 1 (FAT1), which initiates the upregulation of Wnt signaling in glioma. Similarly, another known feature of the GBM pathogenesis is the overexpression of the hepatocyte growth factor (HGF) pathway. The data obtained within The Cancer Genome Atlas Program revealed that FAT1-inactivating mutations account for 1% of GBM cases, whereas approximately 20% of the cases are reported to be related to a copy number loss of FAT1 in GBMs. In addition to genetic aberrations, epigenetic alterations have been observed too, for instance, the hypermethylation of SFRP1, SFRP2, and naked 2 (NKD2) has been characterized and is present in more than 40% of primary-GBM specimens. Moreover, abnormality of the SFRP gene expression is associated with the downregulation of matrix metalloproteinase 2 (MMP-2) and affects GBM cell motility. The overexpression of pleomorphic adenoma gene–like 2 (PLAGL2) suppresses the activity of glioma-initiating cells and NSCs while stimulating their self-renewal potential. Furthermore, transcriptomic data suggest that the differentiation-suppressive effect is associated with PLAGL2 owing to variation in Wnt pathway components (Wnt6, FZD2, and FZD9).

36It is well known that Wnt signaling makes a significant contribution to the progression and regulation of characteristics of brain-associated cancers, and further insight into the molecular mechanism will help to explore the oncogenic effects of this pathway.

5. Therapeutic Targets in the Wnt Signaling Pathway

37In the past, several studies have shown that the aberrant regulation of the Wnt signaling pathway is responsible for the initiation and progression of various immune disorders and cancers, e.g., osteoarthritis, asthma, and CRC in addition to prostate, lung, breast, and thyroid cancer, and CLL. Accordingly, several studies are underway to identify therapeutic targets in the Wnt signaling pathway and to devise new therapies that either antagonize intracellular signaling or block extracellular signals by means of kinase inhibitors, (e.g., small-molecule inhibitors, antibodies, antagonists, or peptides; Table 1). With respect to therapeutic targets, Wnt signaling antagonists are classified into four major classes: ligand/receptor inhibitors, PORCN inhibitors, tankyrase (TNKS) inhibitors, and β-catenin inhibitors.

38As for Wnt signaling, ligand/receptor-targeted drugs binding to ligands or transmembrane proteins represent the main therapeutic approaches that are evaluated in clinical studies on various diseases, cancer in particularl. A large number of drugs are reported, and most of them are monoclonal antibodies (moAbs) such as vantictumab (anti-FZD1, anti-FZD2, anti-FZD5, anti-FZD7, and anti-FZD8), IgG-2919 (anti-FZD5), OTSA101 (an anti-FZD10 antibody–drug conjugate [ADC]), MC-Val-Cit-PAB-MMAE (anti-LGR5 ADC), cirmtuzumab (anti-ROR1), PF-06647020 (anti-PTK7 ADC), OMP-131R10 (anti-RSPO3), sclerostin, OMP-54F28 (anti-FZD8), and ROR1 chimeric antigen receptor (CAR) T cells. All these therapeutics are classified as Wnt ligand/receptor-targeted drugs. PORCN is a key regulator of the Wnt signaling pathway and takes part in the palmitoylation and secretion of Wnt ligands in the endoplasmic reticulum. PORCN inhibitors show promise for the suppression of Wnt signaling and for the treatment of various cancers by blocking the secretion and oligomerization of Wnt receptors. Several small-molecule PORCN inhibitors are being tested in clinical trials including LGK974 (WNT974), inhibitor of Wnt production-2 (IWP-2), WNT-C59 (C59), RXC004, and ETC-159 (ETC-1922159; Table 1).

39Moreover, the inhibitor IWP-2 is proposed for the treatment of cancer, especially CRC due to RNF43 mutations, whereas PORCN inhibitors WNT974 and ETC-159 are applicable to cancer stem cells. Recent studies show that PORCN inhibitor RXC004 strongly increases the effectiveness of immuno-oncology agents such as anti-PD-1 checkpoint inhibitors and enhances immune responses. Nevertheless, several important features need to be considered for future therapeutics, for example, the global blockage of all Wnt secretion, which will undermine gut homeostasis and the effects of canonical and noncanonical Wnt signaling.

40The TNKS enzyme is a member of the poly (ADP ribose) polymerase (PARP) superfamily that adds ADP-ribose onto target proteins. TNKS inhibitors suppress PARylation and degradation of oncogenic signaling proteins such as axin, angiomotin (AMOT), phosphatase and tensin homolog (PTEN), and telomeric repeat-binding factor 1 (TRF1). As a result, the abundance of axin increases, and the overactivated destruction complex inhibits the WNT-β-catenin signaling pathway and telomere shortening and suppresses Yes-associated protein 1 (YAP)-dependent transcription, while PI3K signaling is repressed. Wnt–β-catenin signaling is blocked by various TNKS inhibitors such as tankyrase inhibitor 49 (TNKSi49), XAV939, JW74, AZ1366, IWR-1, NVP-TNKS656, WIKI4, G007-LK, and JW55 in different tumor models. Additionally, TNKS inhibitors are effective in a combination therapy with inhibitors (API2) of AKT (also known as protein kinase B) or with a PI3K inhibitor (BKM120), MEK inhibitor (AZD6244), or an EGFR inhibitor (erlotinib or gefitinib); this combination therapy shows promise against the tumors where β-catenin is overexpressed. Nevertheless, TNKS inhibitors have numerous substrates that are involved in important cellular processes like the regulation of telomere length, Wnt signaling, myelination, and lung fibrogenesis. Although the clinical effectiveness of TNKS inhibitors is high, this inhibition may have acute adverse effects, and these inhibitors have been delayed at the preclinical stage.

41The interaction of β-catenin with transcription factors (TCF or LEF) is an irresistible therapeutic target; in particular, inhibition of β-catenin enhances its degradation and disrupts its binding to TCF or LEF. There are many reported small-molecule compounds that antagonize protein–protein interactions such as, e.g., β-catenin–TCF, stabilized α helix of B-cell lymphoma 9 (SAH-BCL9), BC-2059, PRI-724, CGP049090, PKF115-584, LF3, CWP232228, and MSAB. Other than the above-mentioned compounds, a number of synthetic molecules such as inhibitors of catenin-responsive transcription (iCRT3, iCRT5, and iCRT14), PNU-74654, and BC21 have been identified by high-throughput screening and computational-docking studies. Although these in silico and in vitro screening procedures produce a large number of molecules, the biological activity and binding mechanism for most of them are not clear. Furthermore, there are numerous difficulties, for instance, the binding affinity of β-catenin for TCF is very strong (20 nM), and the role of β-catenin in cell adhesion is unknown where there is an overlap of E-cadherin and TCF interaction sites. Therefore, novel strategies are needed to overcome these hurdles and to target the interaction of β-catenin with various transcription cofactors.

42There are several recently discovered therapeutic targets such as dickkopf family members (DKK1, DKK2, DKK3, and DKK4), which perform a significant function as immunomodulators in immune diseases (as discussed earlier). The DKK1 receptor and cytoskeleton-associated protein 4 (CKAP4) are expressed in tumor cells, suggesting that the inhibition of DKK family members and DKK1–CKAP4 interactions can be examined as a potential therapeutic target, but further studies are still needed to validate this approach.

6. Conclusions and Future Directions of Research

43The Wnt signaling pathway plays an essential role in cell differentiation, division, and proliferation, as well as embryonic growth, stem cell development, tissue regeneration, and immune cell regulatory mechanisms. In this review, we broadly discussed the participation of Wnt signaling in immune cell modulation and the aberrant regulation of Wnt pathway components in cancer and highlighted the relevant therapeutic targets. There are various mutations as well as the overexpression and downregulation of Wnt pathway components: These aberrations can be regarded as causes of immunological disorders and cancers. The role of Wnt signaling in immune cells is becoming an area of active research because of the significant participation of this pathway in the regulation of immune cells apart from cellular survival, proliferation, and development. The functions of Wnt signaling in immune cell–regulatory mechanisms are diverse, for example, the tolerogenic response among DCs, development of NK cells, thymopoiesis of T cells, and B-cell–driven initiation of T-cell activities and Wnt signaling in macrophages. These phenomena are involved in tissue repair, regeneration, and fibrosis. Moreover, all these processes are intricate and lack mechanistic illustrative studies—this situation precludes the invention and formulation of therapeutic strategies and convolutes the outcomes of existing therapeutic modalities. By examining the underlying mechanisms, we revealed that targeting of Wnt signaling can probably overcome all the primary, adaptive, and acquired resistance to cancer immunotherapy.

44Therefore, drug monotherapy is usually insufficient for defeating cancer owing to the complex signaling mechanisms and interactions of pathways. We would like to emphasize that combination therapy is expected to be highly useful for targeting Wnt signaling during cancer treatment in order to help clinicians to attain a successful result. Although there are several Wnt inhibitors that have been studied regarding cancer treatment, it would be worthwhile to extend this research to immune cells.

References 276

1.
Barker N. Adult intestinal stem cells: Critical drivers of epithelial homeostasis and regeneration. Nat. Rev. Mol. Cell Biol. 2014;15:19-33.
Not in our library10.1038/nrm3721
2.
Clevers H., Nusse R. Wnt/beta-catenin signaling and disease. Cell. 2012;149:1192-1205.
Not in our library10.1016/j.cell.2012.05.012
3.
Staal F.J., Luis T.C., Tiemessen M.M. WNT signalling in the immune system: WNT is spreading its wings. Nat. Rev. Immunol. 2008;8:581-593.
Not in our library10.1038/nri2360
4.
Gieseck R.L., Wilson M.S., Wynn T.A. Type 2 immunity in tissue repair and fibrosis. Nat. Rev. Immunol. 2018;18:62-76.
Not in our library10.1038/nri.2017.90
5.
Nusse R., Clevers H. Wnt/beta-Catenin Signaling, Disease, and Emerging Therapeutic Modalities. Cell. 2017;169:985-999.
Not in our library10.1016/j.cell.2017.05.016
6.
MacDonald B.T., Tamai K., He X. Wnt/beta-catenin signaling: Components, mechanisms, and diseases. Dev. Cell. 2009;17:9-26.
Not in our library10.1016/j.devcel.2009.06.016
7.
Zhou Y., Nathans J. Gpr124 controls CNS angiogenesis and blood-brain barrier integrity by promoting ligand-specific canonical wnt signaling. Dev. Cell. 2014;31:248-256.
Not in our library10.1016/j.devcel.2014.08.018
8.
Zhan T., Rindtorff N., Boutros M. Wnt signaling in cancer. Oncogene. 2017;36:1461-1473.
Not in our library10.1038/onc.2016.304
9.
Staal F.J., Arens R. Wnt Signaling as Master Regulator of T-Lymphocyte Responses: Implications for Transplant Therapy. Transplantation. 2016;100:2584-2592.
Not in our library10.1097/tp.0000000000001393
10.
Acebron S.P., Niehrs C. beta-Catenin-Independent Roles of Wnt/LRP6 Signaling. Trends Cell Biol. 2016;26:956-967.
Not in our library10.1016/j.tcb.2016.07.009
11.
Schlessinger K., Hall A., Tolwinski N. Wnt signaling pathways meet Rho GTPases. Genes Dev. 2009;23:265-277.
Not in our library10.1101/gad.1760809
12.
Famili F., Perez L.G., Naber B.A., Noordermeer J.N., Fradkin L.G., Staal F.J. The non-canonical Wnt receptor Ryk regulates hematopoietic stem cell repopulation in part by controlling proliferation and apoptosis. Cell Death Dis. 2016;7:e2479.
Not in our library10.1038/cddis.2016.380
13.
Katoh M. Canonical and non-canonical WNT signaling in cancer stem cells and their niches: Cellular heterogeneity, omics reprogramming, targeted therapy and tumor plasticity (Review). Int. J. Oncol. 2017;51:1357-1369.
Not in our library10.3892/ijo.2017.4129
14.
Yamaguchi T., Yanagisawa K., Sugiyama R., Hosono Y., Shimada Y., Arima C., Kato S., Tomida S., Suzuki M., Osada H., et al. NKX2-1/TITF1/TTF-1-Induced ROR1 is required to sustain EGFR survival signaling in lung adenocarcinoma. Cancer Cell. 2012;21:348-361.
Not in our library10.1016/j.ccr.2012.02.008
15.
The Sec14-like phosphatidylinositol transfer proteins Sec14l3/SEC14L2 act as GTPase proteins to mediate Wnt/Ca2+ signaling · 2017
Not checked
16.
Dejmek J., Safholm A., Kamp Nielsen C., Andersson T., Leandersson K. Wnt-5a/Ca2+-induced NFAT activity is counteracted by Wnt-5a/Yes-Cdc42-casein kinase 1alpha signaling in human mammary epithelial cells. Mol. Cell. Biol. 2006;26:6024-6036.
Not in our library10.1128/mcb.02354-05
17.
Sheldahl L.C., Park M., Malbon C.C., Moon R.T. Protein kinase C is differentially stimulated by Wnt and Frizzled homologs in a G-protein-dependent manner. Curr. Biol. 1999;9:695-698.
Not in our library10.1016/s0960-9822(99)80310-8
18.
Huang T., Xie Z., Wang J., Li M., Jing N., Li L. Nuclear factor of activated T cells (NFAT) proteins repress canonical Wnt signaling via its interaction with Dishevelled (Dvl) protein and participate in regulating neural progenitor cell proliferation and differentiation. J. Biol. Chem. 2011;286:37399-37405.
Not in our library10.1074/jbc.m111.251165
19.
Ishitani T., Kishida S., Hyodo-Miura J., Ueno N., Yasuda J., Waterman M., Shibuya H., Moon R.T., Ninomiya-Tsuji J., Matsumoto K. The TAK1-NLK mitogen-activated protein kinase cascade functions in the Wnt-5a/Ca(2+) pathway to antagonize Wnt/beta-catenin signaling. Mol. Cell. Biol. 2003;23:131-139.
Not in our library10.1128/mcb.23.1.131-139.2003
20.
Lejeune S., Huguet E.L., Hamby A., Poulsom R., Harris A.L. Wnt5a cloning, expression, and up-regulation in human primary breast cancers. Clin. Cancer Res. 1995;1:215-222.
Not in our library
21.
Dejmek J., Dejmek A., Safholm A., Sjolander A., Andersson T. Wnt-5a protein expression in primary dukes B colon cancers identifies a subgroup of patients with good prognosis. Cancer Res. 2005;65:9142-9146.
Not in our library10.1158/0008-5472.can-05-1710
22.
Lento W., Congdon K., Voermans C., Kritzik M., Reya T. Wnt signaling in normal and malignant hematopoiesis. Cold Spring Harb. Perspect. Biol. 2013;5:a008011.
Not in our library10.1101/cshperspect.a008011
23.
Wnt/beta-catenin pathway: modulating anticancer immune response · 2017
No notice
24.
Swafford D., Manicassamy S. Wnt signaling in dendritic cells: Its role in regulation of immunity and tolerance. Discov. Med. 2015;19:303-310.
Not in our library
25.
Modulation of Inflammatory Responses by Wnt/β-catenin Signaling in Dendritic cells: A Novel Immunotherapy target for auto-immunity and Cancer · 2016
Not checked
26.
Zhou J., Cheng P., Youn J.I., Cotter M.J., Gabrilovich D.I. Notch and wingless signaling cooperate in regulation of dendritic cell differentiation. Immunity. 2009;30:845-859.
Not in our library10.1016/j.immuni.2009.03.021
27.
Hong Y., Manoharan I., Suryawanshi A., Majumdar T., Angus-Hill M.L., Koni P.A., Manicassamy B., Mellor A.L., Munn D.H., Manicassamy S. beta-catenin promotes regulatory T-cell responses in tumors by inducing vitamin A metabolism in dendritic cells. Cancer Res. 2015;75:656-665.
Not in our library10.1158/0008-5472.can-14-2377
28.
Hong Y., Manoharan I., Suryawanshi A., Shanmugam A., Swafford D., Ahmad S., Chinnadurai R., Manicassamy B., He Y., Mellor A.L., et al. Deletion of LRP5 and LRP6 in dendritic cells enhances antitumor immunity. Oncoimmunology. 2016;5:e1115941.
Not in our library10.1080/2162402x.2015.1115941
29.
Wang B., Tian T., Kalland K.H., Ke X., Qu Y. Targeting Wnt/beta-Catenin Signaling for Cancer Immunotherapy. Trends Pharmacol. Sci. 2018;39:648-658.
Not in our library10.1016/j.tips.2018.03.008
30.
Xu W.D., Wang J., Yuan T.L., Li Y.H., Yang H., Liu Y., Zhao Y., Herrmann M. Interactions between canonical Wnt signaling pathway and MAPK pathway regulate differentiation, maturation and function of dendritic cells. Cell. Immunol. 2016;310:170-177.
Not in our library10.1016/j.cellimm.2016.09.006
31.
Manicassamy S., Reizis B., Ravindran R., Nakaya H., Salazar-Gonzalez R.M., Wang Y.C., Pulendran B. Activation of beta-catenin in dendritic cells regulates immunity versus tolerance in the intestine. Science. 2010;329:849-853.
Not in our library10.1126/science.1188510
32.
Manoharan I., Hong Y., Suryawanshi A., Angus-Hill M.L., Sun Z., Mellor A.L., Munn D.H., Manicassamy S. TLR2-dependent activation of beta-catenin pathway in dendritic cells induces regulatory responses and attenuates autoimmune inflammation. J. Immunol. 2014;193:4203-4213.
Not in our library10.4049/jimmunol.1400614
33.
Manicassamy S., Ravindran R., Deng J., Oluoch H., Denning T.L., Kasturi S.P., Rosenthal K.M., Evavold B.D., Pulendran B. Toll-like receptor 2-dependent induction of vitamin A-metabolizing enzymes in dendritic cells promotes T regulatory responses and inhibits autoimmunity. Nat. Med. 2009;15:401-409.
Not in our library10.1038/nm.1925
34.
Qian C., Qian L., Yu Y., An H., Guo Z., Han Y., Chen Y., Bai Y., Wang Q., Cao X. Fas signal promotes the immunosuppressive function of regulatory dendritic cells via the ERK/beta-catenin pathway. J. Biol. Chem. 2013;288:27825-27835.
Not in our library10.1074/jbc.m112.425751
35.
Capietto A.H., Kim S., Sanford D.E., Linehan D.C., Hikida M., Kumosaki T., Novack D.V., Faccio R. Down-regulation of PLCgamma2-beta-catenin pathway promotes activation and expansion of myeloid-derived suppressor cells in cancer. J. Exp. Med. 2013;210:2257-2271.
Not in our library10.1084/jem.20130281
36.
Jiang A., Bloom O., Ono S., Cui W., Unternaehrer J., Jiang S., Whitney J.A., Connolly J., Banchereau J., Mellman I. Disruption of E-cadherin-mediated adhesion induces a functionally distinct pathway of dendritic cell maturation. Immunity. 2007;27:610-624.
Not in our library10.1016/j.immuni.2007.08.015
37.
Oderup C., LaJevic M., Butcher E.C. Canonical and noncanonical Wnt proteins program dendritic cell responses for tolerance. J. Immunol. 2013;190:6126-6134.
Not in our library10.4049/jimmunol.1203002
38.
Zhao F., Xiao C., Evans K.S., Theivanthiran T., DeVito N., Holtzhausen A., Liu J., Liu X., Boczkowski D., Nair S., et al. Paracrine Wnt5a-beta-Catenin Signaling Triggers a Metabolic Program that Drives Dendritic Cell Tolerization. Immunity. 2018;48:147-160.e7.
Not in our library10.1016/j.immuni.2017.12.004
39.
Holtzhausen A., Zhao F., Evans K.S., Tsutsui M., Orabona C., Tyler D.S., Hanks B.A. Melanoma-Derived Wnt5a Promotes Local Dendritic-Cell Expression of IDO and Immunotolerance: Opportunities for Pharmacologic Enhancement of Immunotherapy. Cancer Immunol. Res. 2015;3:1082-1095.
Not in our library10.1158/2326-6066.cir-14-0167
40.
Rabinovich G.A., Gabrilovich D., Sotomayor E.M. Immunosuppressive strategies that are mediated by tumor cells. Annu. Rev. Immunol. 2007;25:267-296.
Not in our library10.1146/annurev.immunol.25.022106.141609
41.
Palucka K., Banchereau J. Cancer immunotherapy via dendritic cells. Nat. Rev. Cancer. 2012;12:265-277.
Not in our library10.1038/nrc3258
42.
Liang X., Fu C., Cui W., Ober-Blobaum J.L., Zahner S.P., Shrikant P.A., Clausen B.E., Flavell R.A., Mellman I., Jiang A. beta-catenin mediates tumor-induced immunosuppression by inhibiting cross-priming of CD8(+) T cells. J. Leukoc. Biol. 2014;95:179-190.
Not in our library10.1189/jlb.0613330
43.
Spranger S., Bao R., Gajewski T.F. Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity. Nature. 2015;523:231-235.
Not in our library10.1038/nature14404
44.
Suryawanshi A., Manicassamy S. Tumors induce immune tolerance through activation of beta-catenin/TCF4 signaling in dendritic cells: A novel therapeutic target for cancer immunotherapy. Oncoimmunology. 2015;4:e1052932.
Not in our library10.1080/2162402x.2015.1052932
45.
Wnt1 silences chemokine genes in dendritic cells and induces adaptive immune resistance in lung adenocarcinoma · 2019
Not checked
46.
Grzywacz B., Kataria N., Kataria N., Blazar B.R., Miller J.S., Verneris M.R. Natural killer-cell differentiation by myeloid progenitors. Blood. 2011;117:3548-3558.
Not in our library10.1182/blood-2010-04-281394
47.
Valencia J., Hernandez-Lopez C., Martinez V.G., Hidalgo L., Zapata A.G., Vicente A., Varas A., Sacedon R. Transient beta-catenin stabilization modifies lineage output from human thymic CD34+CD1a- progenitors. J. Leukoc. Biol. 2010;87:405-414.
Not in our library10.1189/jlb.0509344
48.
Ichii M., Frank M.B., Iozzo R.V., Kincade P.W. The canonical Wnt pathway shapes niches supportive of hematopoietic stem/progenitor cells. Blood. 2012;119:1683-1692.
Not in our library10.1182/blood-2011-07-369199
49.
Colucci F., Caligiuri M.A., Di Santo J.P. What does it take to make a natural killer? Nat. Rev. Immunol. 2003;3:413-425.
Not in our library10.1038/nri1088
50.
Niehrs C. Function and biological roles of the Dickkopf family of Wnt modulators. Oncogene. 2006;25:7469-7481.
Not in our library10.1038/sj.onc.1210054
51.
Held W., Clevers H., Grosschedl R. Redundant functions of TCF-1 and LEF-1 during T and NK cell development, but unique role of TCF-1 for Ly49 NK cell receptor acquisition. Eur. J. Immunol. 2003;33:1393-1398.
Not in our library10.1002/eji.200323840
52.
Zhang T., Liu S., Yang P., Han C., Wang J., Liu J., Han Y., Yu Y., Cao X. Fibronectin maintains survival of mouse natural killer (NK) cells via CD11b/Src/beta-catenin pathway. Blood. 2009;114:4081-4088.
Not in our library10.1182/blood-2009-05-219881
53.
Chen Q.Y., Zhang T., Pincus S.H., Wu S., Ricks D., Liu D., Sun Z., Maclaren N., Lan M.S. Human CD1D gene expression is regulated by LEF-1 through distal promoter regulatory elements. J. Immunol. 2010;184:5047-5054.
Not in our library10.4049/jimmunol.0901912
54.
Natural Killer T Cells in Cancer Immunotherapy · 2017
No notice
55.
Chae W.J., Bothwell A.L.M. Canonical and Non-Canonical Wnt Signaling in Immune Cells. Trends Immunol. 2018;39:830-847.
Not in our library10.1016/j.it.2018.08.006
56.
Cui W., Kaech S.M. Generation of effector CD8+ T cells and their conversion to memory T cells. Immunol. Rev. 2010;236:151-166.
Not in our library10.1111/j.1600-065x.2010.00926.x
57.
Schietinger A., Philip M., Krisnawan V.E., Chiu E.Y., Delrow J.J., Basom R.S., Lauer P., Brockstedt D.G., Knoblaugh S.E., Hammerling G.J., et al. Tumor-Specific T Cell Dysfunction Is a Dynamic Antigen-Driven Differentiation Program Initiated Early during Tumorigenesis. Immunity. 2016;45:389-401.
Not in our library10.1016/j.immuni.2016.07.011
58.
T Cell Dysfunction in Cancer Immunity and Immunotherapy · 2019
No notice
59.
Gattinoni L., Zhong X.S., Palmer D.C., Ji Y., Hinrichs C.S., Yu Z., Wrzesinski C., Boni A., Cassard L., Garvin L.M., et al. Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells. Nat. Med. 2009;15:808-813.
Not in our library10.1038/nm.1982
60.
Ma J., Wang R., Fang X., Sun Z. beta-catenin/TCF-1 pathway in T cell development and differentiation. J. Neroimmune Pharmacol. 2012;7:750-762.
Not in our library10.1007/s11481-012-9367-y
61.
Steinke F.C., Xue H.H. From inception to output, Tcf1 and Lef1 safeguard development of T cells and innate immune cells. Immunol. Res. 2014;59:45-55.
Not in our library10.1007/s12026-014-8545-9
62.
Schmitt T.M., Zuniga-Pflucker J.C. Induction of T cell development from hematopoietic progenitor cells by delta-like-1 in vitro. Immunity. 2002;17:749-756.
Not in our library10.1016/s1074-7613(02)00474-0
63.
Jaleco A.C., Neves H., Hooijberg E., Gameiro P., Clode N., Haury M., Henrique D., Parreira L. Differential effects of Notch ligands Delta-1 and Jagged-1 in human lymphoid differentiation. J. Exp. Med. 2001;194:991-1002.
Not in our library10.1084/jem.194.7.991
64.
Tiemessen M.M., Baert M.R., Schonewille T., Brugman M.H., Famili F., Salvatori D.C., Meijerink J.P., Ozbek U., Clevers H., van Dongen J.J., et al. The nuclear effector of Wnt-signaling, Tcf1, functions as a T-cell-specific tumor suppressor for development of lymphomas. PLoS Biol. 2012;10:e1001430.
Not in our library10.1371/journal.pbio.1001430
65.
Steinke F.C., Yu S., Zhou X., He B., Yang W., Zhou B., Kawamoto H., Zhu J., Tan K., Xue H.H. TCF-1 and LEF-1 act upstream of Th-POK to promote the CD4(+) T cell fate and interact with Runx3 to silence Cd4 in CD8(+) T cells. Nat. Immunol. 2014;15:646-656.
Not in our library10.1038/ni.2897
66.
Vacchio M.S., Wang L., Bouladoux N., Carpenter A.C., Xiong Y., Williams L.C., Wohlfert E., Song K.D., Belkaid Y., Love P.E., et al. A ThPOK-LRF transcriptional node maintains the integrity and effector potential of post-thymic CD4+ T cells. Nat. Immunol. 2014;15:947-956.
Not in our library10.1038/ni.2960
67.
Boucheron N., Tschismarov R., Goeschl L., Moser M.A., Lagger S., Sakaguchi S., Winter M., Lenz F., Vitko D., Breitwieser F.P., et al. CD4(+) T cell lineage integrity is controlled by the histone deacetylases HDAC1 and HDAC2. Nat. Immunol. 2014;15:439-448.
Not in our library10.1038/ni.2864
68.
Xing S., Li F., Zeng Z., Zhao Y., Yu S., Shan Q., Li Y., Phillips F.C., Maina P.K., Qi H.H., et al. Tcf1 and Lef1 transcription factors establish CD8(+) T cell identity through intrinsic HDAC activity. Nat. Immunol. 2016;17:695-703.
Not in our library10.1038/ni.3456
69.
Xu Z., Xing S., Shan Q., Gullicksrud J.A., Bair T.B., Du Y., Liu C., Xue H.H. Cutting Edge: Beta-Catenin-Interacting Tcf1 Isoforms Are Essential for Thymocyte Survival but Dispensable for Thymic Maturation Transitions. J. Immunol. 2017;198:3404-3409.
Not in our library10.4049/jimmunol.1602139
70.
Yu Q., Xu M., Sen J.M. Beta-catenin expression enhances IL-7 receptor signaling in thymocytes during positive selection. J. Immunol. 2007;179:126-131.
Not in our library10.4049/jimmunol.179.1.126
71.
Staal F.J., Meeldijk J., Moerer P., Jay P., van de Weerdt B.C., Vainio S., Nolan G.P., Clevers H. Wnt signaling is required for thymocyte development and activates Tcf-1 mediated transcription. Eur. J. Immunol. 2001;31:285-293.
Not in our library10.1002/1521-4141(200101)31:1<285::aid-immu285>3.0.co;2-d
72.
Okamura R.M., Sigvardsson M., Galceran J., Verbeek S., Clevers H., Grosschedl R. Redundant regulation of T cell differentiation and TCRalpha gene expression by the transcription factors LEF-1 and TCF-1. Immunity. 1998;8:11-20.
Not in our library10.1016/s1074-7613(00)80454-9
73.
Pongracz J.E., Parnell S.M., Jones T., Anderson G., Jenkinson E.J. Overexpression of ICAT highlights a role for catenin-mediated canonical Wnt signalling in early T cell development. Eur. J. Immunol. 2006;36:2376-2383.
Not in our library10.1002/eji.200535721
74.
Weerkamp F., Baert M.R., Naber B.A., Koster E.E., de Haas E.F., Atkuri K.R., van Dongen J.J., Herzenberg L.A., Staal F.J. Wnt signaling in the thymus is regulated by differential expression of intracellular signaling molecules. Proc. Natl. Acad. Sci. USA. 2006;103:3322-3326.
Not in our library10.1073/pnas.0511299103
75.
Lin W.W., Nish S.A., Yen B., Chen Y.H., Adams W.C., Kratchmarov R., Rothman N.J., Bhandoola A., Xue H.H., Reiner S.L. CD8(+) T Lymphocyte Self-Renewal during Effector Cell Determination. Cell Rep. 2016;17:1773-1782.
Not in our library10.1016/j.celrep.2016.10.032
76.
Gullicksrud J.A., Li F., Xing S., Zeng Z., Peng W., Badovinac V.P., Harty J.T., Xue H.H. Differential Requirements for Tcf1 Long Isoforms in CD8(+) and CD4(+) T Cell Responses to Acute Viral Infection. J. Immunol. 2017;199:911-919.
Not in our library10.4049/jimmunol.1700595
77.
Yu Q., Sharma A., Oh S.Y., Moon H.G., Hossain M.Z., Salay T.M., Leeds K.E., Du H., Wu B., Waterman M.L., et al. T cell factor 1 initiates the T helper type 2 fate by inducing the transcription factor GATA-3 and repressing interferon-gamma. Nat. Immunol. 2009;10:992-999.
Not in our library10.1038/ni.1762
78.
Global Regulator SATB1 Recruits β-Catenin and Regulates TH2 Differentiation in Wnt-Dependent Manner · 2010
Expression of concern
79.
Muranski P., Borman Z.A., Kerkar S.P., Klebanoff C.A., Ji Y., Sanchez-Perez L., Sukumar M., Reger R.N., Yu Z., Kern S.J., et al. Th17 cells are long lived and retain a stem cell-like molecular signature. Immunity. 2011;35:972-985.
Not in our library10.1016/j.immuni.2011.09.019
80.
Ghosh M.C., Collins G.D., Vandanmagsar B., Patel K., Brill M., Carter A., Lustig A., Becker K.G., Wood W.W., Emeche C.D., et al. Activation of Wnt5A signaling is required for CXC chemokine ligand 12-mediated T-cell migration. Blood. 2009;114:1366-1373.
Not in our library10.1182/blood-2008-08-175869
81.
Staal F.J., Clevers H.C. WNT signalling and haematopoiesis: A WNT-WNT situation. Nat. Rev. Immunol. 2005;5:21-30.
Not in our library10.1038/nri1529
82.
Janovska P., Bryja V. Wnt signalling pathways in chronic lymphocytic leukaemia and B-cell lymphomas. Br. J. Pharmacol. 2017;174:4701-4715.
Not in our library10.1111/bph.13949
83.
Reya T., O’Riordan M., Okamura R., Devaney E., Willert K., Nusse R., Grosschedl R. Wnt signaling regulates B lymphocyte proliferation through a LEF-1 dependent mechanism. Immunity. 2000;13:15-24.
Not in our library10.1016/s1074-7613(00)00004-2
84.
Ranheim E.A., Kwan H.C., Reya T., Wang Y.K., Weissman I.L., Francke U. Frizzled 9 knock-out mice have abnormal B-cell development. Blood. 2005;105:2487-2494.
Not in our library10.1182/blood-2004-06-2334
85.
Dosen G., Tenstad E., Nygren M.K., Stubberud H., Funderud S., Rian E. Wnt expression and canonical Wnt signaling in human bone marrow B lymphopoiesis. BMC Immunol. 2006;7:13.
Not in our library10.1186/1471-2172-7-13
86.
Liang H., Chen Q., Coles A.H., Anderson S.J., Pihan G., Bradley A., Gerstein R., Jurecic R., Jones S.N. Wnt5a inhibits B cell proliferation and functions as a tumor suppressor in hematopoietic tissue. Cancer Cell. 2003;4:349-360.
Not in our library10.1016/s1535-6108(03)00268-x
87.
Kuppers R., Engert A., Hansmann M.L. Hodgkin lymphoma. J. Clin. Investig. 2012;122:3439-3447.
Not in our library10.1172/jci61245
88.
Morrison J.A., Gulley M.L., Pathmanathan R., Raab-Traub N. Differential signaling pathways are activated in the Epstein-Barr virus-associated malignancies nasopharyngeal carcinoma and Hodgkin lymphoma. Cancer Res. 2004;64:5251-5260.
Not in our library10.1158/0008-5472.can-04-0538
89.
Sohlbach K., Moll R., Gossmann J., Nowak O., Barth P., Neubauer A., Huynh M.Q. beta-Catenin signaling: No relevance in Hodgkin lymphoma? Leuk. Lymphoma. 2012;53:996-998.
Not in our library10.3109/10428194.2011.634046
90.
Agostinelli C., Carloni S., Limarzi F., Righi S., Laginestra M.A., Musuraca G., Fiorentino M., Napolitano R., Cuneo A., Vergara D., et al. The emerging role of GSK-3beta in the pathobiology of classical Hodgkin lymphoma. Histopathology. 2017;71:72-80.
Not in our library10.1111/his.13189
91.
Tsou P., Katayama H., Ostrin E.J., Hanash S.M. The Emerging Role of B Cells in Tumor Immunity. Cancer Res. 2016;76:5597-5601.
Not in our library10.1158/0008-5472.can-16-0431
92.
Shen M., Wang J., Ren X. New Insights into Tumor-Infiltrating B Lymphocytes in Breast Cancer: Clinical Impacts and Regulatory Mechanisms. Front. Immunol. 2018;9:470.
Not in our library10.3389/fimmu.2018.00470
93.
Carmi Y., Spitzer M.H., Linde I.L., Burt B.M., Prestwood T.R., Perlman N., Davidson M.G., Kenkel J.A., Segal E., Pusapati G.V., et al. Allogeneic IgG combined with dendritic cell stimuli induce antitumour T-cell immunity. Nature. 2015;521:99-104.
Not in our library10.1038/nature14424
94.
Lv Y., Wang H., Liu Z. The Role of Regulatory B Cells in Patients with Acute Myeloid Leukemia. Med. Sci. Monit. 2019;25:3026-3031.
Not in our library10.12659/msm.915556
95.
Wynn T.A., Chawla A., Pollard J.W. Macrophage biology in development, homeostasis and disease. Nature. 2013;496:445-455.
Not in our library10.1038/nature12034
96.
Ovchinnikov D.A. Macrophages in the embryo and beyond: Much more than just giant phagocytes. Genesis. 2008;46:447-462.
Not in our library10.1002/dvg.20417
97.
Vannella K.M., Wynn T.A. Mechanisms of Organ Injury and Repair by Macrophages. Annu. Rev. Physiol. 2017;79:593-617.
Not in our library10.1146/annurev-physiol-022516-034356
98.
Schaale K., Neumann J., Schneider D., Ehlers S., Reiling N. Wnt signaling in macrophages: Augmenting and inhibiting mycobacteria-induced inflammatory responses. Eur. J. Cell Biol. 2011;90:553-559.
Not in our library10.1016/j.ejcb.2010.11.004
99.
Villar J., Cabrera-Benitez N.E., Ramos-Nuez A., Flores C., Garcia-Hernandez S., Valladares F., Lopez-Aguilar J., Blanch L., Slutsky A.S. Early activation of pro-fibrotic WNT5A in sepsis-induced acute lung injury. Crit. Care. 2014;18:568.
Not in our library10.1186/s13054-014-0568-z
100.
Zhang P., Katz J., Michalek S.M. Glycogen synthase kinase-3beta (GSK3beta) inhibition suppresses the inflammatory response to Francisella infection and protects against tularemia in mice. Mol. Immunol. 2009;46:677-687.
Not in our library10.1016/j.molimm.2008.08.281
101.
Loss of Macrophage Wnt Secretion Improves Remodeling and Function After Myocardial Infarction in Mice · 2017
Not checked
102.
Macrophage-derived extracellular vesicle-packaged WNTs rescue intestinal stem cells and enhance survival after radiation injury · 2016
No notice
103.
Cosin-Roger J., Ortiz-Masia D., Calatayud S., Hernandez C., Esplugues J.V., Barrachina M.D. The activation of Wnt signaling by a STAT6-dependent macrophage phenotype promotes mucosal repair in murine IBD. Mucosal Immunol. 2016;9:986-998.
Not in our library10.1038/mi.2015.123
104.
Lin S.L., Li B., Rao S., Yeo E.J., Hudson T.E., Nowlin B.T., Pei H., Chen L., Zheng J.J., Carroll T.J., et al. Macrophage Wnt7b is critical for kidney repair and regeneration. Proc. Natl. Acad. Sci. USA. 2010;107:4194-4199.
Not in our library10.1073/pnas.0912228107
105.
Yeo E.J., Cassetta L., Qian B.Z., Lewkowich I., Li J.F., Stefater J.A., Smith A.N., Wiechmann L.S., Wang Y., Pollard J.W., et al. Myeloid WNT7b mediates the angiogenic switch and metastasis in breast cancer. Cancer Res. 2014;74:2962-2973.
Not in our library10.1158/0008-5472.can-13-2421
106.
Boulter L., Govaere O., Bird T.G., Radulescu S., Ramachandran P., Pellicoro A., Ridgway R.A., Seo S.S., Spee B., Van Rooijen N., et al. Macrophage-derived Wnt opposes Notch signaling to specify hepatic progenitor cell fate in chronic liver disease. Nat. Med. 2012;18:572-579.
Not in our library10.1038/nm.2667
107.
Shao Y., Zheng Q., Wang W., Xin N., Song X., Zhao C. Biological functions of macrophage-derived Wnt5a, and its roles in human diseases. Oncotarget. 2016;7:67674-67684.
Not in our library10.18632/oncotarget.11874
108.
Pukrop T., Klemm F., Hagemann T., Gradl D., Schulz M., Siemes S., Trumper L., Binder C. Wnt 5a signaling is critical for macrophage-induced invasion of breast cancer cell lines. Proc. Natl. Acad. Sci. USA. 2006;103:5454-5459.
Not in our library10.1073/pnas.0509703103
109.
Naskar D., Maiti G., Chakraborty A., Roy A., Chattopadhyay D., Sen M. Wnt5a-Rac1-NF-kappaB homeostatic circuitry sustains innate immune functions in macrophages. J. Immunol. 2014;192:4386-4397.
Not in our library10.4049/jimmunol.1302817
110.
Bergenfelz C., Medrek C., Ekstrom E., Jirstrom K., Janols H., Wullt M., Bredberg A., Leandersson K. Wnt5a induces a tolerogenic phenotype of macrophages in sepsis and breast cancer patients. J. Immunol. 2012;188:5448-5458.
Not in our library10.4049/jimmunol.1103378
111.
Grivennikov S.I., Wang K., Mucida D., Stewart C.A., Schnabl B., Jauch D., Taniguchi K., Yu G.Y., Osterreicher C.H., Hung K.E., et al. Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature. 2012;491:254-258.
Not in our library10.1038/nature11465
112.
Mutant p53 cancers reprogram macrophages to tumor supporting macrophages via exosomal miR-1246 · 2018
No notice
113.
Pillay J., den Braber I., Vrisekoop N., Kwast L.M., de Boer R.J., Borghans J.A., Tesselaar K., Koenderman L. In vivo labeling with 2H2O reveals a human neutrophil lifespan of 5.4 days. Blood. 2010;116:625-627.
Not in our library10.1182/blood-2010-01-259028
114.
Park Y.M., Bochner B.S. Eosinophil survival and apoptosis in health and disease. Allergy Asthma Immunol. Res. 2010;2:87-101.
Not in our library10.4168/aair.2010.2.2.87
115.
Jung Y.S., Lee H.Y., Kim S.D., Park J.S., Kim J.K., Suh P.G., Bae Y.S. Wnt5a stimulates chemotactic migration and chemokine production in human neutrophils. Exp. Mol. Med. 2013;45:e27.
Not in our library10.1038/emm.2013.48
116.
Januskevicius A., Vaitkiene S., Gosens R., Janulaityte I., Hoppenot D., Sakalauskas R., Malakauskas K. Eosinophils enhance WNT-5a and TGF-beta1 genes expression in airway smooth muscle cells and promote their proliferation by increased extracellular matrix proteins production in asthma. BMC Pulm. Med. 2016;16:94.
Not in our library10.1186/s12890-016-0254-9
117.
Rodewald H.R., Feyerabend T.B. Widespread immunological functions of mast cells: Fact or fiction? Immunity. 2012;37:13-24.
Not in our library10.1016/j.immuni.2012.07.007
118.
Gurish M.F., Austen K.F. Developmental origin and functional specialization of mast cell subsets. Immunity. 2012;37:25-33.
Not in our library10.1016/j.immuni.2012.07.003
119.
Yamaguchi T., Nishijima M., Tashiro K., Kawabata K. Wnt-beta-Catenin Signaling Promotes the Maturation of Mast Cells. BioMed Res. Int. 2016;2016:2048987.
Not in our library10.1155/2016/2048987
120.
Dyduch G., Kaczmarczyk K., Okon K. Mast cells and cancer: Enemies or allies? Pol. J. Pathol. 2012;63:1-7.
Not in our library
121.
β-Catenin, a novel prognostic marker for breast cancer: Its roles in cyclin D1 expression and cancer progression · 2000
Not checked
122.
Geyer F.C., Lacroix-Triki M., Savage K., Arnedos M., Lambros M.B., MacKay A., Natrajan R., Reis-Filho J.S. beta-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation. Mod. Pathol. 2011;24:209-231.
Not in our library10.1038/modpathol.2010.205
123.
Khramtsov A.I., Khramtsova G.F., Tretiakova M., Huo D., Olopade O.I., Goss K.H. Wnt/beta-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome. Am. J. Pathol. 2010;176:2911-2920.
Not in our library10.2353/ajpath.2010.091125
124.
Li S., Li S., Sun Y., Li L. The expression of beta-catenin in different subtypes of breast cancer and its clinical significance. Tumour Biol. 2014;35:7693-7698.
Not in our library10.1007/s13277-014-1975-0
125.
Chakrabarti R., Wei Y., Hwang J., Hang X., Andres Blanco M., Choudhury A., Tiede B., Romano R.A., DeCoste C., Mercatali L., et al. DeltaNp63 promotes stem cell activity in mammary gland development and basal-like breast cancer by enhancing Fzd7 expression and Wnt signalling. Nat. Cell Biol. 2014;16:1004-1015.
Not in our library10.1038/ncb3040
126.
Klauzinska M., Baljinnyam B., Raafat A., Rodriguez-Canales J., Strizzi L., Greer Y.E., Rubin J.S., Callahan R. Rspo2/Int7 regulates invasiveness and tumorigenic properties of mammary epithelial cells. J. Cell. Physiol. 2012;227:1960-1971.
Not in our library10.1002/jcp.22924
127.
Cui B., Zhang S., Chen L., Yu J., Widhopf G.F., Fecteau J.F., Rassenti L.Z., Kipps T.J. Targeting ROR1 inhibits epithelial-mesenchymal transition and metastasis. Cancer Res. 2013;73:3649-3660.
Not in our library10.1158/0008-5472.can-12-3832
128.
WNT signaling modulates PD-L1 expression in the stem cell compartment of triple-negative breast cancer · 2019
No notice
129.
Xu Z., Robitaille A.M., Berndt J.D., Davidson K.C., Fischer K.A., Mathieu J., Potter J.C., Ruohola-Baker H., Moon R.T. Wnt/beta-catenin signaling promotes self-renewal and inhibits the primed state transition in naive human embryonic stem cells. Proc. Natl. Acad. Sci. USA. 2016;113:E6382-E6390.
Not in our library10.1073/pnas.1613849113
130.
Merino V.F., Cho S., Liang X., Park S., Jin K., Chen Q., Pan D., Zahnow C.A., Rein A.R., Sukumar S. Inhibitors of STAT3, beta-catenin, and IGF-1R sensitize mouse PIK3CA-mutant breast cancer to PI3K inhibitors. Mol. Oncol. 2017;11:552-566.
Not in our library10.1002/1878-0261.12053
131.
Chiang K.C., Yeh C.N., Chung L.C., Feng T.H., Sun C.C., Chen M.F., Jan Y.Y., Yeh T.S., Chen S.C., Juang H.H. WNT-1 inducible signaling pathway protein-1 enhances growth and tumorigenesis in human breast cancer. Sci. Rep. 2015;5:8686.
Not in our library10.1038/srep08686
132.
Cleary A.S., Leonard T.L., Gestl S.A., Gunther E.J. Tumour cell heterogeneity maintained by cooperating subclones in Wnt-driven mammary cancers. Nature. 2014;508:113-117.
Not in our library10.1038/nature13187
133.
Lindvall C., Evans N.C., Zylstra C.R., Li Y., Alexander C.M., Williams B.O. The Wnt signaling receptor Lrp5 is required for mammary ductal stem cell activity and Wnt1-induced tumorigenesis. J. Biol. Chem. 2006;281:35081-35087.
Not in our library10.1074/jbc.m607571200
134.
MiR-31 promotes mammary stem cell expansion and breast tumorigenesis by suppressing Wnt signaling antagonists · 2017
Corrected
135.
Liu S., Cong Y., Wang D., Sun Y., Deng L., Liu Y., Martin-Trevino R., Shang L., McDermott S.P., Landis M.D., et al. Breast cancer stem cells transition between epithelial and mesenchymal states reflective of their normal counterparts. Stem Cell Rep. 2014;2:78-91.
Not in our library10.1016/j.stemcr.2013.11.009
136.
Lim S.K., Lu S.Y., Kang S.A., Tan H.J., Li Z., Adrian Wee Z.N., Guan J.S., Reddy Chichili V.P., Sivaraman J., Putti T., et al. Wnt Signaling Promotes Breast Cancer by Blocking ITCH-Mediated Degradation of YAP/TAZ Transcriptional Coactivator WBP2. Cancer Res. 2016;76:6278-6289.
Not in our library10.1158/0008-5472.can-15-3537
137.
Luis T.C., Ichii M., Brugman M.H., Kincade P., Staal F.J. Wnt signaling strength regulates normal hematopoiesis and its deregulation is involved in leukemia development. Leukemia. 2012;26:414-421.
Not in our library10.1038/leu.2011.387
138.
Kamran S., Awan S.A., Ahmad K.N., Iqbal Y. Acute Myeloid Leukemia with t(8;21)(q22;q22) and Trisomy 4: A Rare Occurrence in a Female Child. Cureus. 2019;11:e3885.
Not in our library10.7759/cureus.3885
139.
Sakoda T., Kikushige Y., Miyamoto T., Akashi K. Canonical Wnt Pathway Is Activated in Myeloid Leukemia Stem Cells Via Hematopoietic Cell Kinase That Is Phosphorylated By an Autocrine TIM-3/Galectin-9 Signaling. 2017.
Not in our library
140.
Plasma Exosomes as Markers of Therapeutic Response in Patients with Acute Myeloid Leukemia · 2014
No notice
141.
Yeung J., Esposito M.T., Gandillet A., Zeisig B.B., Griessinger E., Bonnet D., So C.W. beta-Catenin mediates the establishment and drug resistance of MLL leukemic stem cells. Cancer Cell. 2010;18:606-618.
Not in our library10.1016/j.ccr.2010.10.032
142.
Lane S.W., Wang Y.J., Lo Celso C., Ragu C., Bullinger L., Sykes S.M., Ferraro F., Shterental S., Lin C.P., Gilliland D.G., et al. Differential niche and Wnt requirements during acute myeloid leukemia progression. Blood. 2011;118:2849-2856.
Not in our library10.1182/blood-2011-03-345165
143.
Wang Y., Krivtsov A.V., Sinha A.U., North T.E., Goessling W., Feng Z., Zon L.I., Armstrong S.A. The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML. Science. 2010;327:1650-1653.
Not in our library10.1126/science.1186624
144.
Cheng C.K., Li L., Cheng S.H., Lau K.M., Chan N.P., Wong R.S., Shing M.M., Li C.K., Ng M.H. Transcriptional repression of the RUNX3/AML2 gene by the t(8;21) and inv(16) fusion proteins in acute myeloid leukemia. Blood. 2008;112:3391-3402.
Not in our library10.1182/blood-2008-02-137083
145.
Muller-Tidow C., Steffen B., Cauvet T., Tickenbrock L., Ji P., Diederichs S., Sargin B., Kohler G., Stelljes M., Puccetti E., et al. Translocation products in acute myeloid leukemia activate the Wnt signaling pathway in hematopoietic cells. Mol. Cell. Biol. 2004;24:2890-2904.
Not in our library10.1128/mcb.24.7.2890-2904.2004
146.
Kode A., Mosialou I., Manavalan S.J., Rathinam C.V., Friedman R.A., Teruya-Feldstein J., Bhagat G., Berman E., Kousteni S. FoxO1-dependent induction of acute myeloid leukemia by osteoblasts in mice. Leukemia. 2016;30:1-13.
Not in our library10.1038/leu.2015.161
147.
Ferrando A.A. The role of NOTCH1 signaling in T-ALL. Hematol. Am. Soc. Hematol. Educ. Program. 2009;2009:353-361.
Not in our library10.1182/asheducation-2009.1.353
148.
Kaveri D., Kastner P., Dembele D., Nerlov C., Chan S., Kirstetter P. beta-Catenin activation synergizes with Pten loss and Myc overexpression in Notch-independent T-ALL. Blood. 2013;122:694-704.
Not in our library10.1182/blood-2012-12-471904
149.
Guo W., Lasky J.L., Chang C.J., Mosessian S., Lewis X., Xiao Y., Yeh J.E., Chen J.Y., Iruela-Arispe M.L., Varella-Garcia M., et al. Multi-genetic events collaboratively contribute to Pten-null leukaemia stem-cell formation. Nature. 2008;453:529-533.
Not in our library10.1038/nature06933
150.
Giambra V., Jenkins C.E., Lam S.H., Hoofd C., Belmonte M., Wang X., Gusscott S., Gracias D., Weng A.P. Leukemia stem cells in T-ALL require active Hif1alpha and Wnt signaling. Blood. 2015;125:3917-3927.
Not in our library10.1182/blood-2014-10-609370
151.
Kipps T.J., Stevenson F.K., Wu C.J., Croce C.M., Packham G., Wierda W.G., O’Brien S., Gribben J., Rai K. Chronic lymphocytic leukaemia. Nat. Rev. Dis. Primers. 2017;3:16096.
Not in our library10.1038/nrdp.2016.96
152.
Lu D., Zhao Y., Tawatao R., Cottam H.B., Sen M., Leoni L.M., Kipps T.J., Corr M., Carson D.A. Activation of the Wnt signaling pathway in chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. USA. 2004;101:3118-3123.
Not in our library10.1073/pnas.0308648100
153.
Concurrent epigenetic silencing of wnt/β-catenin pathway inhibitor genes in B cell chronic lymphocytic leukaemia · 2012
Not checked
154.
Wang L., Shalek A.K., Lawrence M., Ding R., Gaublomme J.T., Pochet N., Stojanov P., Sougnez C., Shukla S.A., Stevenson K.E., et al. Somatic mutation as a mechanism of Wnt/beta-catenin pathway activation in CLL. Blood. 2014;124:1089-1098.
Not in our library10.1182/blood-2014-01-552067
155.
Fukuda T., Chen L., Endo T., Tang L., Lu D., Castro J.E., Widhopf G.F., Rassenti L.Z., Cantwell M.J., Prussak C.E., et al. Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a. Proc. Natl. Acad. Sci. USA. 2008;105:3047-3052.
Not in our library10.1073/pnas.0712148105
156.
Howe D., Bromidge T. Variation of LEF-1 mRNA expression in low-grade B-cell non-Hodgkin’s lymphoma. Leuk. Res. 2006;30:29-32.
Not in our library10.1016/j.leukres.2005.06.004
157.
Haderk F., Schulz R., Iskar M., Cid L.L., Worst T., Willmund K.V., Schulz A., Warnken U., Seiler J., Benner A., et al. Tumor-derived exosomes modulate PD-L1 expression in monocytes. Sci. Immunol. 2017;2.
Not in our library10.1126/sciimmunol.aah5509
158.
Ren Z., van Andel H., de Lau W., Hartholt R.B., Maurice M.M., Clevers H., Kersten M.J., Spaargaren M., Pals S.T. Syndecan-1 promotes Wnt/beta-catenin signaling in multiple myeloma by presenting Wnts and R-spondins. Blood. 2018;131:982-994.
Not in our library10.1182/blood-2017-07-797050
159.
Haseeb M., Anwar M.A., Choi S. Molecular Interactions between Innate and Adaptive Immune Cells in Chronic Lymphocytic Leukemia and Their Therapeutic Implications. Front. Immunol. 2018;9:2720.
Not in our library10.3389/fimmu.2018.02720
160.
Chiurillo M.A. Role of the Wnt/beta-catenin pathway in gastric cancer: An in-depth literature review. World J. Exp. Med. 2015;5:84-102.
Not in our library10.5493/wjem.v5.i2.84
161.
Seshagiri S., Stawiski E.W., Durinck S., Modrusan Z., Storm E.E., Conboy C.B., Chaudhuri S., Guan Y., Janakiraman V., Jaiswal B.S., et al. Recurrent R-spondin fusions in colon cancer. Nature. 2012;488:660-664.
Not in our library10.1038/nature11282
162.
Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487:330-337.
Not in our library10.1038/nature11252
163.
Bass A.J., Lawrence M.S., Brace L.E., Ramos A.H., Drier Y., Cibulskis K., Sougnez C., Voet D., Saksena G., Sivachenko A., et al. Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion. Nat. Genet. 2011;43:964-968.
Not in our library10.1038/ng.936
164.
Sanz-Pamplona R., Lopez-Doriga A., Pare-Brunet L., Lazaro K., Bellido F., Alonso M.H., Ausso S., Guino E., Beltran S., Castro-Giner F., et al. Exome Sequencing Reveals AMER1 as a Frequently Mutated Gene in Colorectal Cancer. Clin. Cancer Res. 2015;21:4709-4718.
Not in our library10.1158/1078-0432.ccr-15-0159
165.
Wang W., Pan Q., Fuhler G.M., Smits R., Peppelenbosch M.P. Action and function of Wnt/beta-catenin signaling in the progression from chronic hepatitis C to hepatocellular carcinoma. J. Gastroenterol. 2017;52:419-431.
Not in our library10.1007/s00535-016-1299-5
166.
Matano M., Date S., Shimokawa M., Takano A., Fujii M., Ohta Y., Watanabe T., Kanai T., Sato T. Modeling colorectal cancer using CRISPR-Cas9-mediated engineering of human intestinal organoids. Nat. Med. 2015;21:256-262.
Not in our library10.1038/nm.3802
167.
Drost J., van Jaarsveld R.H., Ponsioen B., Zimberlin C., van Boxtel R., Buijs A., Sachs N., Overmeer R.M., Offerhaus G.J., Begthel H., et al. Sequential cancer mutations in cultured human intestinal stem cells. Nature. 2015;521:43-47.
Not in our library10.1038/nature14415
168.
Christie M., Jorissen R.N., Mouradov D., Sakthianandeswaren A., Li S., Day F., Tsui C., Lipton L., Desai J., Jones I.T., et al. Different APC genotypes in proximal and distal sporadic colorectal cancers suggest distinct WNT/beta-catenin signalling thresholds for tumourigenesis. Oncogene. 2013;32:4675-4682.
Not in our library10.1038/onc.2012.486
169.
Buchert M., Athineos D., Abud H.E., Burke Z.D., Faux M.C., Samuel M.S., Jarnicki A.G., Winbanks C.E., Newton I.P., Meniel V.S., et al. Genetic dissection of differential signaling threshold requirements for the Wnt/beta-catenin pathway in vivo. PLoS Genet. 2010;6:e1000816.
Not in our library10.1371/journal.pgen.1000816
170.
Dow L.E., O’Rourke K.P., Simon J., Tschaharganeh D.F., van Es J.H., Clevers H., Lowe S.W. Apc Restoration Promotes Cellular Differentiation and Reestablishes Crypt Homeostasis in Colorectal Cancer. Cell. 2015;161:1539-1552.
Not in our library10.1016/j.cell.2015.05.033
171.
Circulating exosomal microRNA-203 is associated with metastasis possibly via inducing tumor-associated macrophages in colorectal cancer · 2017
No notice
172.
Yong X., Tang B., Xiao Y.F., Xie R., Qin Y., Luo G., Hu C.J., Dong H., Yang S.M. Helicobacter pylori upregulates Nanog and Oct4 via Wnt/beta-catenin signaling pathway to promote cancer stem cell-like properties in human gastric cancer. Cancer Lett. 2016;374:292-303.
Not in our library10.1016/j.canlet.2016.02.032
173.
Santos J.C., Carrasco-Garcia E., Garcia-Puga M., Aldaz P., Montes M., Fernandez-Reyes M., de Oliveira C.C., Lawrie C.H., Arauzo-Bravo M.J., Ribeiro M.L., et al. SOX9 Elevation Acts with Canonical WNT Signaling to Drive Gastric Cancer Progression. Cancer Res. 2016;76:6735-6746.
Not in our library10.1158/0008-5472.can-16-1120
174.
Peng Q., Chen L., Wu W., Wang J., Zheng X., Chen Z., Jiang Q., Han J., Wei L., Wang L., et al. EPH receptor A2 governs a feedback loop that activates Wnt/beta-catenin signaling in gastric cancer. Cell Death Dis. 2018;9:1146.
Not in our library10.1038/s41419-018-1164-y
175.
Ara H., Takagishi M., Enomoto A., Asai M., Ushida K., Asai N., Shimoyama Y., Kaibuchi K., Kodera Y., Takahashi M. Role for Daple in non-canonical Wnt signaling during gastric cancer invasion and metastasis. Cancer Sci. 2016;107:133-139.
Not in our library10.1111/cas.12848
176.
Van de Wetering M., Francies H.E., Francis J.M., Bounova G., Iorio F., Pronk A., van Houdt W., van Gorp J., Taylor-Weiner A., Kester L., et al. Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell. 2015;161:933-945.
Not in our library10.1016/j.cell.2015.03.053
177.
Shi Y., Bai J., Guo S., Wang J. Wntless Is Highly Expressed in Advanced-Stage Intrahepatic Cholangiocarcinoma. Tohoku J. Exp. Med. 2018;244:195-199.
Not in our library10.1620/tjem.244.195
178.
Goeppert B., Konermann C., Schmidt C.R., Bogatyrova O., Geiselhart L., Ernst C., Gu L., Becker N., Zucknick M., Mehrabi A., et al. Global alterations of DNA methylation in cholangiocarcinoma target the Wnt signaling pathway. Hepatology. 2014;59:544-554.
Not in our library10.1002/hep.26721
179.
Zheng Y., Zhou C., Yu X.X., Wu C., Jia H.L., Gao X.M., Yang J.M., Wang C.Q., Luo Q., Zhu Y., et al. Osteopontin promotes metastasis of intrahepatic cholangiocarcinoma through recruiting MAPK1 and mediating Ser675 phosphorylation of beta-Catenin. Cell Death Dis. 2018;9:179.
Not in our library10.1038/s41419-017-0226-x
180.
Boulter L., Guest R.V., Kendall T.J., Wilson D.H., Wojtacha D., Robson A.J., Ridgway R.A., Samuel K., Van Rooijen N., Barry S.T., et al. WNT signaling drives cholangiocarcinoma growth and can be pharmacologically inhibited. J. Clin. Investig. 2015;125:1269-1285.
Not in our library10.1172/jci76452
181.
Loilome W., Bungkanjana P., Techasen A., Namwat N., Yongvanit P., Puapairoj A., Khuntikeo N., Riggins G.J. Activated macrophages promote Wnt/beta-catenin signaling in cholangiocarcinoma cells. Tumor Biol. 2014;35:5357-5367.
Not in our library10.1007/s13277-014-1698-2
182.
Chan-On W., Nairismagi M.L., Ong C.K., Lim W.K., Dima S., Pairojkul C., Lim K.H., McPherson J.R., Cutcutache I., Heng H.L., et al. Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers. Nat. Genet. 2013;45:1474-1478.
Not in our library10.1038/ng.2806
183.
Oliveira L.A., Oshima C.T.F., Soffner P.A., Silva M.S., Lins R.R., Malinverni A.C.M., Waisberg J. The Canonical Wnt Pathway in Gastric Carcinoma. Arq. Bras. Cir. Dig. 2019;32:e1414.
Not in our library10.1590/0102-672020180001e1414
184.
Noelanders R., Vleminckx K. How Wnt Signaling Builds the Brain: Bridging Development and Disease. Neuroscientist. 2017;23:314-329.
Not in our library10.1177/1073858416667270
185.
Takahashi H., Liu F.C. Genetic patterning of the mammalian telencephalon by morphogenetic molecules and transcription factors. Birth Defects Res. C Embryo Today. 2006;78:256-266.
Not in our library10.1002/bdrc.20077
186.
Kalani M.Y., Cheshier S.H., Cord B.J., Bababeygy S.R., Vogel H., Weissman I.L., Palmer T.D., Nusse R. Wnt-mediated self-renewal of neural stem/progenitor cells. Proc. Natl. Acad. Sci. USA. 2008;105:16970-16975.
Not in our library10.1073/pnas.0808616105
187.
Chenn A., Walsh C.A. Regulation of cerebral cortical size by control of cell cycle exit in neural precursors. Science. 2002;297:365-369.
Not in our library10.1126/science.1074192
188.
Zechner D., Fujita Y., Hulsken J., Muller T., Walther I., Taketo M.M., Crenshaw E.B., Birchmeier W., Birchmeier C. beta-Catenin signals regulate cell growth and the balance between progenitor cell expansion and differentiation in the nervous system. Dev. Biol. 2003;258:406-418.
Not in our library10.1016/s0012-1606(03)00123-4
189.
Birchmeier C., Birchmeier W., Gherardi E., Vande Woude G.F. Met, metastasis, motility and more. Nat. Rev. Mol. Cell Biol. 2003;4:915-925.
Not in our library10.1038/nrm1261
190.
Kong D.S., Song S.Y., Kim D.H., Joo K.M., Yoo J.S., Koh J.S., Dong S.M., Suh Y.L., Lee J.I., Park K., et al. Prognostic significance of c-Met expression in glioblastomas. Cancer. 2009;115:140-148.
Not in our library10.1002/cncr.23972
191.
Kim K.H., Seol H.J., Kim E.H., Rheey J., Jin H.J., Lee Y., Joo K.M., Lee J., Nam D.H. Wnt/beta-catenin signaling is a key downstream mediator of MET signaling in glioblastoma stem cells. Neuro Oncol. 2013;15:161-171.
Not in our library10.1093/neuonc/nos299
192.
Morris L.G., Kaufman A.M., Gong Y., Ramaswami D., Walsh L.A., Turcan S., Eng S., Kannan K., Zou Y., Peng L., et al. Recurrent somatic mutation of FAT1 in multiple human cancers leads to aberrant Wnt activation. Nat. Genet. 2013;45:253-261.
Not in our library10.1038/ng.2538
193.
Roth W., Wild-Bode C., Platten M., Grimmel C., Melkonyan H.S., Dichgans J., Weller M. Secreted Frizzled-related proteins inhibit motility and promote growth of human malignant glioma cells. Oncogene. 2000;19:4210-4220.
Not in our library10.1038/sj.onc.1203783
194.
Schiefer L., Visweswaran M., Perumal V., Arfuso F., Groth D., Newsholme P., Warrier S., Dharmarajan A. Epigenetic regulation of the secreted frizzled-related protein family in human glioblastoma multiforme. Cancer Gene Ther. 2014;21:297-303.
Not in our library10.1038/cgt.2014.30
195.
Foltz G., Yoon J.G., Lee H., Ma L., Tian Q., Hood L., Madan A. Epigenetic regulation of wnt pathway antagonists in human glioblastoma multiforme. Genes Cancer. 2010;1:81-90.
Not in our library10.1177/1947601909356103
196.
Zheng H., Ying H., Wiedemeyer R., Yan H., Quayle S.N., Ivanova E.V., Paik J.H., Zhang H., Xiao Y., Perry S.R., et al. PLAGL2 regulates Wnt signaling to impede differentiation in neural stem cells and gliomas. Cancer Cell. 2010;17:497-509.
Not in our library10.1016/j.ccr.2010.03.020
197.
Moon R.T., Kohn A.D., De Ferrari G.V., Kaykas A. WNT and beta-catenin signalling: Diseases and therapies. Nat. Rev. Genet. 2004;5:691-701.
Not in our library10.1038/nrg1427
198.
Najdi R., Holcombe R.F., Waterman M.L. Wnt signaling and colon carcinogenesis: Beyond APC. J. Carcinog. 2011;10:5.
Not in our library10.4103/1477-3163.78111
199.
Gurney A., Axelrod F., Bond C.J., Cain J., Chartier C., Donigan L., Fischer M., Chaudhari A., Ji M., Kapoun A.M., et al. Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors. Proc. Natl. Acad. Sci. USA. 2012;109:11717-11722.
Not in our library10.1073/pnas.1120068109
200.
Steinhart Z., Pavlovic Z., Chandrashekhar M., Hart T., Wang X., Zhang X., Robitaille M., Brown K.R., Jaksani S., Overmeer R., et al. Genome-wide CRISPR screens reveal a Wnt-FZD5 signaling circuit as a druggable vulnerability of RNF43-mutant pancreatic tumors. Nat. Med. 2017;23:60-68.
Not in our library10.1038/nm.4219
201.
Nielsen T.O., Poulin N.M., Ladanyi M. Synovial sarcoma: Recent discoveries as a roadmap to new avenues for therapy. Cancer Discov. 2015;5:124-134.
Not in our library10.1158/2159-8290.cd-14-1246
202.
Gong X., Azhdarinia A., Ghosh S.C., Xiong W., An Z., Liu Q., Carmon K.S. LGR5-Targeted Antibody-Drug Conjugate Eradicates Gastrointestinal Tumors and Prevents Recurrence. Mol. Cancer Ther. 2016;15:1580-1590.
Not in our library10.1158/1535-7163.mct-16-0114
203.
Zhang S., Cui B., Lai H., Liu G., Ghia E.M., Widhopf G.F., Zhang Z., Wu C.C., Chen L., Wu R., et al. Ovarian cancer stem cells express ROR1, which can be targeted for anti-cancer-stem-cell therapy. Proc. Natl. Acad. Sci. USA. 2014;111:17266-17271.
Not in our library10.1073/pnas.1419599111
204.
Damelin M., Bankovich A., Bernstein J., Lucas J., Chen L., Williams S., Park A., Aguilar J., Ernstoff E., Charati M., et al. A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressions. Sci. Transl. Med. 2017;9.
Not in our library10.1126/scitranslmed.aag2611
205.
Storm E.E., Durinck S., de Sousa e Melo F., Tremayne J., Kljavin N., Tan C., Ye X., Chiu C., Pham T., Hongo J.A., et al. Targeting PTPRK-RSPO3 colon tumours promotes differentiation and loss of stem-cell function. Nature. 2016;529:97-100.
Not in our library10.1038/nature16466
206.
Appelman-Dijkstra N.M., Papapoulos S.E. Sclerostin Inhibition in the Management of Osteoporosis. Calcif. Tissue Int. 2016;98:370-380.
Not in our library10.1007/s00223-016-0126-6
207.
Le P.N., McDermott J.D., Jimeno A. Targeting the Wnt pathway in human cancers: Therapeutic targeting with a focus on OMP-54F28. Pharmacol. Ther. 2015;146:1-11.
Not in our library10.1016/j.pharmthera.2014.08.005
208.
Berger C., Sommermeyer D., Hudecek M., Berger M., Balakrishnan A., Paszkiewicz P.J., Kosasih P.L., Rader C., Riddell S.R. Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cells. Cancer Immunol. Res. 2015;3:206-216.
Not in our library10.1158/2326-6066.cir-14-0163
209.
Poulsen A., Ho S.Y., Wang W., Alam J., Jeyaraj D.A., Ang S.H., Tan E.S., Lin G.R., Cheong V.W., Ke Z., et al. Pharmacophore Model for Wnt/Porcupine Inhibitors and Its Use in Drug Design. J. Chem. Inf. Model. 2015;55:1435-1448.
Not in our library10.1021/acs.jcim.5b00159
210.
Langton P.F., Kakugawa S., Vincent J.P. Making, Exporting, and Modulating Wnts. Trends Cell Biol. 2016;26:756-765.
Not in our library10.1016/j.tcb.2016.05.011
211.
Agarwal P., Zhang B., Ho Y., Cook A., Li L., Mikhail F.M., Wang Y., McLaughlin M.E., Bhatia R. Enhanced targeting of CML stem and progenitor cells by inhibition of porcupine acyltransferase in combination with TKI. Blood. 2017;129:1008-1020.
Not in our library10.1182/blood-2016-05-714089
212.
Chen B., Dodge M.E., Tang W., Lu J., Ma Z., Fan C.W., Wei S., Hao W., Kilgore J., Williams N.S., et al. Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nat. Chem. Biol. 2009;5:100-107.
Not in our library10.1038/nchembio.137
213.
Proffitt K.D., Madan B., Ke Z., Pendharkar V., Ding L., Lee M.A., Hannoush R.N., Virshup D.M. Pharmacological inhibition of the Wnt acyltransferase PORCN prevents growth of WNT-driven mammary cancer. Cancer Res. 2013;73:502-507.
Not in our library10.1158/0008-5472.can-12-2258
214.
Bhamra I., Armer R., Bingham M., Eagle C., Cook A.E., Phillips C., Woodcock S. Abstract 3764: Porcupine inhibitor RXC004 enhances immune response in pre-clinical models of cancer. Cancer Res. 2018;78:3764.
Not in our library10.1158/1538-7445.am2018-3764
215.
Madan B., Ke Z., Harmston N., Ho S.Y., Frois A.O., Alam J., Jeyaraj D.A., Pendharkar V., Ghosh K., Virshup I.H., et al. Wnt addiction of genetically defined cancers reversed by PORCN inhibition. Oncogene. 2016;35:2197-2207.
Not in our library10.1038/onc.2015.280
216.
Tammela T., Sanchez-Rivera F.J., Cetinbas N.M., Wu K., Joshi N.S., Helenius K., Park Y., Azimi R., Kerper N.R., Wesselhoeft R.A., et al. A Wnt-producing niche drives proliferative potential and progression in lung adenocarcinoma. Nature. 2017;545:355-359.
Not in our library10.1038/nature22334
217.
Valenta T., Degirmenci B., Moor A.E., Herr P., Zimmerli D., Moor M.B., Hausmann G., Cantu C., Aguet M., Basler K. Wnt Ligands Secreted by Subepithelial Mesenchymal Cells Are Essential for the Survival of Intestinal Stem Cells and Gut Homeostasis. Cell Rep. 2016;15:911-918.
Not in our library10.1016/j.celrep.2016.03.088
218.
Canonical Wnt signaling is antagonized by noncanonical Wnt5a in hepatocellular carcinoma cells · 2009
No notice
219.
Boone J.D., Arend R.C., Johnston B.E., Cooper S.J., Gilchrist S.A., Oelschlager D.K., Grizzle W.E., McGwin G., Gangrade A., Straughn J.M., et al. Targeting the Wnt/beta-catenin pathway in primary ovarian cancer with the porcupine inhibitor WNT974. Lab. Investig. 2016;96:249-259.
Not in our library10.1038/labinvest.2015.150
220.
Liu J., Pan S., Hsieh M.H., Ng N., Sun F., Wang T., Kasibhatla S., Schuller A.G., Li A.G., Cheng D., et al. Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974. Proc. Natl. Acad. Sci. USA. 2013;110:20224-20229.
Not in our library10.1073/pnas.1314239110
221.
Solzak J.P., Atale R.V., Hancock B.A., Sinn A.L., Pollok K.E., Jones D.R., Radovich M. Dual PI3K and Wnt pathway inhibition is a synergistic combination against triple negative breast cancer. NPJ Breast Cancer. 2017;3:17.
Not in our library10.1038/s41523-017-0016-8
222.
Jiang X., Hao H.X., Growney J.D., Woolfenden S., Bottiglio C., Ng N., Lu B., Hsieh M.H., Bagdasarian L., Meyer R., et al. Inactivating mutations of RNF43 confer Wnt dependency in pancreatic ductal adenocarcinoma. Proc. Natl. Acad. Sci. USA. 2013;110:12649-12654.
Not in our library10.1073/pnas.1307218110
223.
Cheng Y., Phoon Y.P., Jin X., Chong S.Y., Ip J.C., Wong B.W., Lung M.L. Wnt-C59 arrests stemness and suppresses growth of nasopharyngeal carcinoma in mice by inhibiting the Wnt pathway in the tumor microenvironment. Oncotarget. 2015;6:14428-14439.
Not in our library10.18632/oncotarget.3982
224.
Koo B.K., van Es J.H., van den Born M., Clevers H. Porcupine inhibitor suppresses paracrine Wnt-driven growth of Rnf43;Znrf3-mutant neoplasia. Proc. Natl. Acad. Sci. USA. 2015;112:7548-7550.
Not in our library10.1073/pnas.1508113112
225.
Kahn M. Can we safely target the WNT pathway? Nat. Rev. Drug Discov. 2014;13:513-532.
Not in our library10.1038/nrd4233
226.
Huang S.M., Mishina Y.M., Liu S., Cheung A., Stegmeier F., Michaud G.A., Charlat O., Wiellette E., Zhang Y., Wiessner S., et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature. 2009;461:614-620.
Not in our library10.1038/nature08356
227.
Stakheev D., Taborska P., Strizova Z., Podrazil M., Bartunkova J., Smrz D. The WNT/beta-catenin signaling inhibitor XAV939 enhances the elimination of LNCaP and PC-3 prostate cancer cells by prostate cancer patient lymphocytes in vitro. Sci. Rep. 2019;9:4761.
Not in our library10.1038/s41598-019-41182-5
228.
Inhibition of Tankyrases Induces Axin Stabilization and Blocks Wnt Signalling in Breast Cancer Cells · 2012
No notice
229.
Li C., Zheng X., Han Y., Lv Y., Lan F., Zhao J. XAV939 inhibits the proliferation and migration of lung adenocarcinoma A549 cells through the WNT pathway. Oncol. Lett. 2018;15:8973-8982.
Not in our library10.3892/ol.2018.8491
230.
Scarborough H.A., Helfrich B.A., Casas-Selves M., Schuller A.G., Grosskurth S.E., Kim J., Tan A.C., Chan D.C., Zhang Z., Zaberezhnyy V., et al. AZ1366: An Inhibitor of Tankyrase and the Canonical Wnt Pathway that Limits the Persistence of Non-Small Cell Lung Cancer Cells Following EGFR Inhibition. Clin. Cancer Res. 2017;23:1531-1541.
Not in our library10.1158/1078-0432.ccr-16-1179
231.
Waaler J., Machon O., Tumova L., Dinh H., Korinek V., Wilson S.R., Paulsen J.E., Pedersen N.M., Eide T.J., Machonova O., et al. A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice. Cancer Res. 2012;72:2822-2832.
Not in our library10.1158/0008-5472.can-11-3336
232.
Arques O., Chicote I., Puig I., Tenbaum S.P., Argiles G., Dienstmann R., Fernandez N., Caratu G., Matito J., Silberschmidt D., et al. Tankyrase Inhibition Blocks Wnt/beta-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer. Clin. Cancer Res. 2016;22:644-656.
Not in our library10.1158/1078-0432.ccr-14-3081
233.
Lau T., Chan E., Callow M., Waaler J., Boggs J., Blake R.A., Magnuson S., Sambrone A., Schutten M., Firestein R., et al. A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth. Cancer Res. 2013;73:3132-3144.
Not in our library10.1158/0008-5472.can-12-4562
234.
Martins-Neves S.R., Paiva-Oliveira D.I., Fontes-Ribeiro C., Bovee J., Cleton-Jansen A.M., Gomes C.M.F. IWR-1, a tankyrase inhibitor, attenuates Wnt/beta-catenin signaling in cancer stem-like cells and inhibits in vivo the growth of a subcutaneous human osteosarcoma xenograft. Cancer Lett. 2018;414:1-15.
Not in our library10.1016/j.canlet.2017.11.004
235.
Waaler J., Machon O., von Kries J.P., Wilson S.R., Lundenes E., Wedlich D., Gradl D., Paulsen J.E., Machonova O., Dembinski J.L., et al. Novel synthetic antagonists of canonical Wnt signaling inhibit colorectal cancer cell growth. Cancer Res. 2011;71:197-205.
Not in our library10.1158/0008-5472.can-10-1282
236.
Hua Z., Bregman H., Buchanan J.L., Chakka N., Guzman-Perez A., Gunaydin H., Huang X., Gu Y., Berry V., Liu J., et al. Development of novel dual binders as potent, selective, and orally bioavailable tankyrase inhibitors. J. Med. Chem. 2013;56:10003-10015.
Not in our library10.1021/jm401317z
237.
James R.G., Davidson K.C., Bosch K.A., Biechele T.L., Robin N.C., Taylor R.J., Major M.B., Camp N.D., Fowler K., Martins T.J., et al. WIKI4, a novel inhibitor of tankyrase and Wnt/ss-catenin signaling. PLoS ONE. 2012;7:e50457.
Not in our library10.1371/journal.pone.0050457
238.
Fang F., VanCleave A., Helmuth R., Torres H., Rickel K., Wollenzien H., Sun H., Zeng E., Zhao J., Tao J. Targeting the Wnt/beta-catenin pathway in human osteosarcoma cells. Oncotarget. 2018;9:36780-36792.
Not in our library10.18632/oncotarget.26377
239.
Jang G.B., Hong I.S., Kim R.J., Lee S.Y., Park S.J., Lee E.S., Park J.H., Yun C.H., Chung J.U., Lee K.J., et al. Wnt/beta-Catenin Small-Molecule Inhibitor CWP232228 Preferentially Inhibits the Growth of Breast Cancer Stem-like Cells. Cancer Res. 2015;75:1691-1702.
Not in our library10.1158/0008-5472.can-14-2041
240.
Cha J.Y., Jung J.-E., Lee K.-H., Briaud I., Tenzin F., Jung H.K., Pyon Y., Lee D., Chung J.U., Lee J.H., et al. Anti-tumor activity of novel small molecule Wnt signaling inhibitor, CWP232291, in multiple myeloma. Blood. 2010;116:3038.
Not in our library10.1182/blood.v116.21.3038.3038
241.
Fiskus W., Sharma S., Saha S., Shah B., Devaraj S.G., Sun B., Horrigan S., Leveque C., Zu Y., Iyer S., et al. Pre-clinical efficacy of combined therapy with novel beta-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cells. Leukemia. 2015;29:1267-1278.
Not in our library10.1038/leu.2014.340
242.
Fang L., Zhu Q., Neuenschwander M., Specker E., Wulf-Goldenberg A., Weis W.I., von Kries J.P., Birchmeier W. A Small-Molecule Antagonist of the beta-Catenin/TCF4 Interaction Blocks the Self-Renewal of Cancer Stem Cells and Suppresses Tumorigenesis. Cancer Res. 2016;76:891-901.
Not in our library10.1158/0008-5472.can-15-1519
243.
Direct Targeting of β-Catenin by a Small Molecule Stimulates Proteasomal Degradation and Suppresses Oncogenic Wnt/β-Catenin Signaling · 2016
Not checked
244.
Takada K., Zhu D., Bird G.H., Sukhdeo K., Zhao J.J., Mani M., Lemieux M., Carrasco D.E., Ryan J., Horst D., et al. Targeted disruption of the BCL9/beta-catenin complex inhibits oncogenic Wnt signaling. Sci. Transl. Med. 2012;4:148ra117.
Not in our library10.1126/scitranslmed.3003808
245.
Chen Z., Venkatesan A.M., Dehnhardt C.M., Dos Santos O., Delos Santos E., Ayral-Kaloustian S., Chen L., Geng Y., Arndt K.T., Lucas J., et al. 2,4-Diamino-quinazolines as inhibitors of beta-catenin/Tcf-4 pathway: Potential treatment for colorectal cancer. Bioorg. Med. Chem. Lett. 2009;19:4980-4983.
Not in our library10.1016/j.bmcl.2009.07.070
246.
Rahmani F., Amerizadeh F., Hassanian S.M., Hashemzehi M., Nasiri S.N., Fiuji H., Ferns G.A., Khazaei M., Avan A. PNU-74654 enhances the antiproliferative effects of 5-FU in breast cancer and antagonizes thrombin-induced cell growth via the Wnt pathway. J. Cell. Physiol. 2019;234:14123-14132.
Not in our library10.1002/jcp.28104
247.
Wnt signaling blockage inhibits cell proliferation and migration, and induces apoptosis in triple-negative breast cancer cells · 2013
No notice
248.
Lepourcelet M., Chen Y.N., France D.S., Wang H., Crews P., Petersen F., Bruseo C., Wood A.W., Shivdasani R.A. Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex. Cancer Cell. 2004;5:91-102.
Not in our library10.1016/s1535-6108(03)00334-9
249.
Wei W., Chua M.S., Grepper S., So S. Small molecule antagonists of Tcf4/beta-catenin complex inhibit the growth of HCC cells in vitro and in vivo. Int. J. Cancer. 2010;126:2426-2436.
Not in our library10.1002/ijc.24810
250.
Yao H., Ashihara E., Strovel J.W., Nakagawa Y., Kuroda J., Nagao R., Tanaka R., Yokota A., Takeuchi M., Hayashi Y., et al. AV-65, a novel Wnt/beta-catenin signal inhibitor, successfully suppresses progression of multiple myeloma in a mouse model. Blood Cancer J. 2011;1:e43.
Not in our library10.1038/bcj.2011.41
251.
Jarde T., Evans R.J., McQuillan K.L., Parry L., Feng G.J., Alvares B., Clarke A.R., Dale T.C. In vivo and in vitro models for the therapeutic targeting of Wnt signaling using a Tet-ODeltaN89beta-catenin system. Oncogene. 2013;32:883-893.
Not in our library10.1038/onc.2012.103
252.
Grandy D., Shan J., Zhang X., Rao S., Akunuru S., Li H., Zhang Y., Alpatov I., Zhang X.A., Lang R.A., et al. Discovery and characterization of a small molecule inhibitor of the PDZ domain of dishevelled. J. Biol. Chem. 2009;284:16256-16263.
Not in our library10.1074/jbc.m109.009647
253.
Fujii N., You L., Xu Z., Uematsu K., Shan J., He B., Mikami I., Edmondson L.R., Neale G., Zheng J., et al. An antagonist of dishevelled protein-protein interaction suppresses beta-catenin-dependent tumor cell growth. Cancer Res. 2007;67:573-579.
Not in our library10.1158/0008-5472.can-06-2726
254.
DeAlmeida V.I., Miao L., Ernst J.A., Koeppen H., Polakis P., Rubinfeld B. The soluble wnt receptor Frizzled8CRD-hFc inhibits the growth of teratocarcinomas in vivo. Cancer Res. 2007;67:5371-5379.
Not in our library10.1158/0008-5472.can-07-0266
255.
Li H., Yu C., Jiang J., Huang C., Yao X., Xu Q., Yu F., Lou L., Fang J. An anti-HER2 antibody conjugated with monomethyl auristatin E is highly effective in HER2-positive human gastric cancer. Cancer Biol. Ther. 2016;17:346-354.
Not in our library10.1080/15384047.2016.1139248
256.
Chartier C., Raval J., Axelrod F., Bond C., Cain J., Dee-Hoskins C., Ma S., Fischer M.M., Shah J., Wei J., et al. Therapeutic Targeting of Tumor-Derived R-Spondin Attenuates beta-Catenin Signaling and Tumorigenesis in Multiple Cancer Types. Cancer Res. 2016;76:713-723.
Not in our library10.1158/0008-5472.can-15-0561
257.
Liu C., Yu X. ADP-ribosyltransferases and poly ADP-ribosylation. Curr. Protein Pept. Sci. 2015;16:491-501.
Not in our library10.2174/1389203716666150504122435
258.
Kulak O., Chen H., Holohan B., Wu X., He H., Borek D., Otwinowski Z., Yamaguchi K., Garofalo L.A., Ma Z., et al. Disruption of Wnt/beta-Catenin Signaling and Telomeric Shortening Are Inextricable Consequences of Tankyrase Inhibition in Human Cells. Mol. Cell. Biol. 2015;35:2425-2435.
Not in our library10.1128/mcb.00392-15
259.
Tankyrase Inhibitors Target YAP by Stabilizing Angiomotin Family Proteins · 2015
Not checked
260.
Stratford E.W., Daffinrud J., Munthe E., Castro R., Waaler J., Krauss S., Myklebost O. The tankyrase-specific inhibitor JW74 affects cell cycle progression and induces apoptosis and differentiation in osteosarcoma cell lines. Cancer Med. 2014;3:36-46.
Not in our library10.1002/cam4.170
261.
Quackenbush K.S., Bagby S., Tai W.M., Messersmith W.A., Schreiber A., Greene J., Kim J., Wang G., Purkey A., Pitts T.M., et al. The novel tankyrase inhibitor (AZ1366) enhances irinotecan activity in tumors that exhibit elevated tankyrase and irinotecan resistance. Oncotarget. 2016;7:28273-28285.
Not in our library10.18632/oncotarget.8626
262.
Busch A.M., Johnson K.C., Stan R.V., Sanglikar A., Ahmed Y., Dmitrovsky E., Freemantle S.J. Evidence for tankyrases as antineoplastic targets in lung cancer. BMC Cancer. 2013;13:211.
Not in our library10.1186/1471-2407-13-211
263.
Schoumacher M., Hurov K.E., Lehar J., Yan-Neale Y., Mishina Y., Sonkin D., Korn J.M., Flemming D., Jones M.D., Antonakos B., et al. Inhibiting Tankyrases sensitizes KRAS-mutant cancer cells to MEK inhibitors via FGFR2 feedback signaling. Cancer Res. 2014;74:3294-3305.
Not in our library10.1158/0008-5472.can-14-0138-t
264.
Wang H., Lu B., Castillo J., Zhang Y., Yang Z., McAllister G., Lindeman A., Reece-Hoyes J., Tallarico J., Russ C., et al. Tankyrase Inhibitor Sensitizes Lung Cancer Cells to Endothelial Growth Factor Receptor (EGFR) Inhibition via Stabilizing Angiomotins and Inhibiting YAP Signaling. J. Biol. Chem. 2016;291:15256-15266.
Not in our library10.1074/jbc.m116.722967
265.
Riffell J.L., Lord C.J., Ashworth A. Tankyrase-targeted therapeutics: Expanding opportunities in the PARP family. Nat. Rev. Drug Discov. 2012;11:923-936.
Not in our library10.1038/nrd3868
266.
Valenta T., Hausmann G., Basler K. The many faces and functions of beta-catenin. EMBO J. 2012;31:2714-2736.
Not in our library10.1038/emboj.2012.150
267.
Zhou H., Mak P.Y., Mu H., Mak D.H., Zeng Z., Cortes J., Liu Q., Andreeff M., Carter B.Z. Combined inhibition of beta-catenin and Bcr-Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo. Leukemia. 2017;31:2065-2074.
Not in our library10.1038/leu.2017.87
268.
Trautmann M., Sievers E., Aretz S., Kindler D., Michels S., Friedrichs N., Renner M., Kirfel J., Steiner S., Huss S., et al. SS18-SSX fusion protein-induced Wnt/beta-catenin signaling is a therapeutic target in synovial sarcoma. Oncogene. 2014;33:5006-5016.
Not in our library10.1038/onc.2013.443
269.
Sukhdeo K., Mani M., Zhang Y., Dutta J., Yasui H., Rooney M.D., Carrasco D.E., Zheng M., He H., Tai Y.T., et al. Targeting the beta-catenin/TCF transcriptional complex in the treatment of multiple myeloma. Proc. Natl. Acad. Sci. USA. 2007;104:7516-7521.
Not in our library10.1073/pnas.0610299104
270.
Kim J.Y., Lee H.Y., Park K.K., Choi Y.K., Nam J.S., Hong I.S. CWP232228 targets liver cancer stem cells through Wnt/beta-catenin signaling: A novel therapeutic approach for liver cancer treatment. Oncotarget. 2016;7:20395-20409.
Not in our library10.18632/oncotarget.7954
271.
Gonsalves F.C., Klein K., Carson B.B., Katz S., Ekas L.A., Evans S., Nagourney R., Cardozo T., Brown A.M., DasGupta R. An RNAi-based chemical genetic screen identifies three small-molecule inhibitors of the Wnt/wingless signaling pathway. Proc. Natl. Acad. Sci. USA. 2011;108:5954-5963.
Not in our library10.1073/pnas.1017496108
272.
Trosset J.Y., Dalvit C., Knapp S., Fasolini M., Veronesi M., Mantegani S., Gianellini L.M., Catana C., Sundstrom M., Stouten P.F., et al. Inhibition of protein-protein interactions: The discovery of druglike beta-catenin inhibitors by combining virtual and biophysical screening. Proteins. 2006;64:60-67.
Not in our library10.1002/prot.20955
273.
Tian W., Han X., Yan M., Xu Y., Duggineni S., Lin N., Luo G., Li Y.M., Han X., Huang Z., et al. Structure-based discovery of a novel inhibitor targeting the beta-catenin/Tcf4 interaction. Biochemistry. 2012;51:724-731.
Not in our library10.1021/bi201428h
274.
Hahne G., Grossmann T.N. Direct targeting of beta-catenin: Inhibition of protein-protein interactions for the inactivation of Wnt signaling. Bioorg. Med. Chem. 2013;21:4020-4026.
Not in our library10.1016/j.bmc.2013.02.050
275.
Chae W.J., Ehrlich A.K., Chan P.Y., Teixeira A.M., Henegariu O., Hao L., Shin J.H., Park J.H., Tang W.H., Kim S.T., et al. The Wnt Antagonist Dickkopf-1 Promotes Pathological Type 2 Cell-Mediated Inflammation. Immunity. 2016;44:246-258.
Not in our library10.1016/j.immuni.2016.01.008
276.
Kimura H., Fumoto K., Shojima K., Nojima S., Osugi Y., Tomihara H., Eguchi H., Shintani Y., Endo H., Inoue M., et al. CKAP4 is a Dickkopf1 receptor and is involved in tumor progression. J. Clin. Investig. 2016;126:2689-2705.
Not in our library10.1172/jci84658

Cited by papers we hold 2

Pathogenesis and treatment of Sjogren’s syndrome: Review and update · 2023
No notice
Anticancer Potential of Furanocoumarins: Mechanistic and Therapeutic Aspects · 2020
No notice

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.